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GSprotein!coupled!receptor!
GRPS1Sassociated!scaffold!protein!or!GRASP!!
GSprotein!regulatory!kinase!
Healthy!control!
Ionotropic!glutamate!receptor!
Intracellular!inositol!1,4,5Striphosphate!
Long!term!depression!
Long!term!potentiation!
Major!depression!
Major!depression!without!psychosis!
Major!depression!with!psychosis!
Metabotropic!glutamate!receptor!
![5R,10S]S[+]S5SmethylS10,11S!dihydroS5HSdibenzo[a,d]cycloheptenS5,10Simine!
2SMethylS6S(phenylethynyl)pyridine!
3S![(2SmethylS1,3SthiazolS4Syl)ethynyl]Spyridine!
Mammalian!target!of!rapomycin!
NSmethylSDSaspartate!receptor!
FERM!(4.1!protein,!ezrin,!radixin!and!moesin)!and!PDZ!(post!synaptic!density!protein,!Drosophila!
disc!large!tumor!suppressor,!and!zonula!occludensS1!protein)!domainScontaining!protein!4!
Per!oral!
Positive!allosteric!modulators!
Phencyclidine!
Prefrontal!cortex!
PI3!Kinase!and!its!enhancer!
ProteinSkinase!C!
Phospholipase!C!
Protein!phosphatase!1!
Protein!phosphatase!2B/calcineurin!
Postsynaptic!density!
PostSsynaptic!density!95!
ProlineSrich!tyrosine!kinase/cell!adhesion!kinase!ß!
Reference!single!nucleotide!polymorphisms!
MembraneSassociated!guanylate!kinase!invertedS2!
SH3!and!multiple!ankyrin!repeat!domains!
Subcutaneous!
Seven!in!absentia!homolog!1.!
Schizophrenia!
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Abstract!
!
Metabotropic! glutamate! receptor! subtype! 5! (mGluR5)Stargeting! therapeutics! display! a! favourable!
profile! of! effects! in! preclinical! paradigms,! particularly! for! the! treatment! of! cognitive! dysfunction.! It!
however!remains!unclear!whether!mGluR5!plays!a!causal!or!epiphenomenal!role!in!the!pathophysiS
ology! of! schizophrenia.! It! is! important! to! understand! the! aspects! of! mGluR5! that! might! be! altered!
within! the! pathological! condition,! as! this! could! have! implications! for! novel! drugs! targeted! at! these!
systems!in!the!patient.!This!thesis!therefore!aimed!to!deconstruct![at!least!some]!of!the!complexities!
of!mGluR5!in!schizophrenia,!with!a!focus!on!potential!dysregulation!of!mGluR5,!predominately!utilisS
ing!human!tissues!(postmortem!brain!tissues!and!DNA!samples!derived!from!schizophrenia!patients).!
!
Considering! many! symptoms! associated! with! schizophrenia! overlap! with! other! closely! related! neuS
ropsychiatric!disorders,!the!first!study!in!this!thesis!(Chapter!2)!aimed!to!address!whether!mGluR5!
alterations!were!specific!to!a!particular!set!of!symptoms!(such!as!depressive!symptoms!or!psychotic!
symptoms,! or! a! combination! thereof).! To! do! this,! mGluR5! binding! was! performed! in! postmortem!
samples!from!the!anterior!cingulate!cortex,!a!region!that!modulates!cognitive!and!emotional!processS
es,!of!subjects!with!schizophrenia,!major!depression!(with!or!without!psychosis)!or!bipolar!disorder.!
The! results! revealed! that! mGluR5! binding! was! unaltered! across! all! neuropsychiatric! pathologies,!
providing! preliminary! evidence! that! mGluR5! is! not! affected,! at! least! in! this! region.! Binding! studies!
provide!valuable!insight!into!the!ability!of!a!receptor!to!interact!with!ligands!and!are!thus!useful!for!
determining! the! therapeutic! utility! of! a! receptor;! however! this! method! is! unable! to! detect! wider!
changes,!such!as!altered!regulation,!which!may!be!underlying!the!observed!pathologies.!
!
Building! on! from! this! work,! Chapter! 3! aimed! to! explore! whether! dysregulation! was! present! within!
the! mGluR5! system! in! schizophrenia.! Postmortem! samples! from! the! dorsolateral! prefrontal! cortex!
(DLPFC;!BA46!involved!in!higher!executive!and!cognitive!processes)!of!schizophrenia!subjects!were!
examined.! mGluR5,! and! proteins! known! to! regulate! mGluR5! trafficking,! endocytosis! and! signalling!
(Norbin,!Tamalin!and!Preso1)!were!examined.!This!study!was!also!expanded!to!include!measures!of!
mGluR5! mRNA! levels! in! the! same! subjects! (data! contributed! by! the! S.! Fung! and! C.S.! Weickert).! ToS
gether,!this!study!revealed!that!although!mGluR5!mRNA!levels!were!unaltered,!mGluR5!protein!levels!
were!greatly!increased!in!this!brain!region.!Conversely,!mGluR5!endogenous!regulators!(Norbin,!TaS
malin! and! Preso1)! were! significantly! decreased! in! this! region.! Interestingly,! mGluR5! protein! levels!
were! correlated! with! levels! of! mGluR5! mRNA! and! the! measured! mGluR5! endogenous! regulators! in!
control!subjects,!but!this!correlation!was!lost!in!schizophrenia!subjects.!These!results!strongly!supS
port!the!presence!of!mGluR5!dysregulation!in!schizophrenia,!at!least!in!this!region.!!
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The! work! in! Chapter! 4! aimed! to! determine! whether! these! findings! in! the! DLPFC! were! exclusive! to!
this!brain!region,!or!whether!they!extended!to!the!hippocampus.!The!hippocampus!is!another!region!
involved!in!schizophrenia!pathology,!which!is!involved!in!learning!and!memory!functions.!Extensive!
animal!and!cellSbased!data!suggests!mGluR5!critically!mediates!synaptic!plasticity!specifically!in!the!
CA1! subregion! of! the! hippocampus.! The! results! from! this! study! thus! found,! that! similarly! to! the!
DLPFC,!mGluR5!was!increased!in!the!CA1!region.!In!contrast!to!the!DLPFC,!however,!levels!of!mGluR5!
endogenous! regulators! were! significantly! increased! in! this! region,! and! no! correlations! between!
mGluR5! and! the! mGluR5! endogenous! regulators! were! observed.! These! findings! suggest! that! whilst!
alterations! to! mGluR5! extend! to! the! CA1! region,! the! function,! signalling,! or! regulation! of! mGluR5!
might!be!brainSregion!specific.!This!work!nonetheless!also!supports!that!mGluR5!is!dysregulated!in!
schizophrenia.!
!
In!Chapters!3!and!4,!the!influence!of!commonly!used!antipsychotic!drugs!(APDs)!on!mGluR5!was!exS
amined.!In!this!series!of!studies,!adult!male!rats!were!treated!with!either!haloperidol!(a!first!generaS
tion!APD)!or!olanzapine!(a!second!generation!APD)!for!short,!medium!and!longSterm!durations!(APDS
treated!rat!brains!contributed!by!X.F.!Huang).!!The!protein!levels!of!mGluR5!and!mGluR5!endogenous!
regulators!were!subsequently!measured!in!regions!corresponding!to!the!human!studies,!the!PFC!and!
hippocampus.!The!results!indicated!that!commonly!used!APDs!do!not!influence!the!mGluR5!system,!
suggesting! that! the! postmortem! findings! in! Chapters! 2,! 3! and! 4! are! not! confounded! by! premortem!
mediation! history.! These! findings! also! suggest! that! novel! drugs! to! correct! potential! changes! in!
mGluR5! might! be! useful! as! an! adjunct! treatment! with! current! APDs,! to! target! the! observed! alteraS
tions!in!the!postmortem!human!tissues!that!are!not!targeted!by!current!APDs.!
!
The! knowledge! regarding! mGluR5! is! becoming! increasingly! substantial.! Nonetheless,! very! little! is!
known!about!the!role!of!the!GRM5!gene,)encoding!for!mGluR5,!in!the!genetic!susceptibility!to!schizoS
phrenia.!Chapter!5!thus!aimed!to!determine!whether!single!nucleotide!polymorphisms!(SNPs)!within!
the!GRM5!gene!are!associated!with!schizophrenia!diagnosis!in!a!large!Caucasian!caseScontrol!populaS
tion.! In! light! of! my! previous! works! from! Chapters! 3! and! 4,! indicating! mGluR5! dysregulation! at! the!
protein!level,!SNPs!located!in!the!3’!untranslated!region!of!GRM5!were!selected,!as!this!is!a!genomic!
region!that!is!highly!involved!in!protein!conformation!and!regulation!of!regions!responsible!for!proS
teinSprotein! interactions.! Furthermore,! due! to! the! extensive! evidence! that! mGluR5! underlies! cogniS
tive!processes,!effects!of!genetic!variability!within!the!chosen!SNPs!were!analysed!for!their!effects!on!
various!measures!of!cognitive!function!(data!contributed!by!M.J.!Green).!As!hypothesised,!the!measS
ured!SNPs!within!GRM5!were!differentially!association!with!schizophrenia!diagnosis.!Further,!genetic!
variability! within! GRM5! affected! and/or! was! able! to! significantly! predict! the! level! of! cognitive! dysS
function!in!schizophrenia!patients.!Interestingly!in!this!study,!all!findings!were!sexSspecific,!suggestS
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ing! that! GRM5/mGluR5! may! be! differently! regulated! in! men! and! women! with! schizophrenia.! NoneS
theless,!the!association!of!SNPs!located!within!the!3’!untranslated!region!of!GRM5!contributes!to!the!
substantial!evidence!presented!in!this!thesis!that!mGluR5!is!dysregulated!in!the!pathology!of!schizoS
phrenia,!and!supports!that!mGluR5!has!a!modulatory!effect!on!cognitive!function!in!humans,!not!just!
animals.!
!
Using!a!systematic!approach!to!analyse!mGluR5!from!the!geneSlevel!to!proteinSlevel,!and!further,!in!
human!cognitive!performance,!the!findings!from!this!thesis!provide!the!first!compelling!evidence!that!
mGluR5! is! dysregulated! in! schizophrenia.! Although! further! studies! are! required! to! investigate! the!
exact!mechanisms!responsible!for!this!dysregulation,!the!findings!presented!here!support!the!develS
opment!of!agents!that!modulate!mGluR5!regulation!and/or!signalling!to!treat!cognitive!dysfunctions!
in!patients!with!schizophrenia.!!

!
!
!
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Chapter(One!
!

!
This!chapter!is!published!in!part:)
•

Matosin!N,!Lum!JS,!FernandezSEnright!F,!Newell!KA.!Shifting!towards!a!model!of!mGluR5!dysregulaS
tion!in!schizophrenia:!consequences!for!future!schizophrenia!treatment.!Special!issue:!“mGluRs:!5!
years!on”,!Neuropharmacology.!Under!review!with!Guest!Editors.!

•

Matosin!N,!Newell!KA.!Metabotropic!glutamate!receptor!5!in!the!pathology!and!treatment!of!schizS
ophrenia.!Neuroscience)and)Biobehavioural)Reviews!2013,!37(3).!

•

Newell!KA,!Matosin!N.!Rethinking!metabotropic!glutamate!receptor!5!pathological!findings!in!psyS
chiatric!disorders:!implications!for!the!future!of!novel!therapeutics.!BMC)Psychiatry.!2014.!14(23).!

•

Newell!KA,!Matosin!N,!Lum!J.!Chapter!5:!Metabotropic!glutamate!receptors!in!the!pathophysiology!
and!treatment!of!schizophrenia!and!major!depression.!Metabotropic)Glutamate)Receptors:)Molecu6
lar)Mechanisms,)Role)in)Neurological)Disorders)and)Pharmacological)Effects.!Nova!Publishers.!2014.!!

!

1.1!!

Introduction!

!
1.1.1! What!is!schizophrenia?!
Schizophrenia!is!a!severe!neuropsychiatric!disorder,!characterised!by!disturbances!of!thought,!emoS
tion! and! behaviour.! Despite! decades! of! research,! the! exact! causes! remain! unknown.! Schizophrenia!
emerges!primarily!in!early!adulthood!and!affects!approximately!1%!of!the!general!population!(World!
Health!Organization,!2006).!Although!there!is!a!strong!heritability!of!schizophrenia!(~80%),!studies!
have!not!identified!one!single!genetic!origin,!but!rather!over!1500!single!nucleotide!polymorphisms!
(SNPs)!have!been!associated!with!the!disorder!(Purcell!et!al.,!2014;!Ripke!et!al.,!2013).!Environmental!
influences,!such!as!earlySlife!stress!and!cannabis!use,!have!also!been!linked!to!schizophrenia!vulneraS
bility!(van!Os!et!al.,!2010).!Accumulating!evidence!thus!indicates!that!the!aetiology!of!schizophrenia!is!
polygenic,! with! both! genetic! and! environmental! factors! involved! (Altamura! et! al.,! 2011;! Dickinson,!
2014;!Ehrenreich!and!Nave,!2014;!Leask,!2004).!!
!
The!symptoms!of!schizophrenia!are!broadly!characterised!into!positive,!negative!and!cognitive!cateS
gories!(Eaton!et!al.,!1995).!Each!patient!displays!a!combination!of!these!symptoms,!with!differing!seS
verities! that! vary! according! to! the! stage! of! disease! progression! (Tandon! et! al.,! 2008;! Tandon! et! al.,!
2009).! Positive! symptoms! (such! as! hallucinations! and! delusions)! emerge! gradually! at! the! onset! of!
disease,!marking!the!first!psychotic!episode!(Tandon!et!al.,!2009).!Whilst!positive!symptoms!are!the!
most!striking!indications!of!schizophrenia,!negative!(depressiveSlike!symptoms)!and!cognitive!sympS
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toms!(deficits!in!attention,!concentration,!learning,!memory,!language,!psychomotor!speed!and!higher!
order!thinking)!cause!greater!debilitation,!as!they!are!strongly!linked!with!the!individual’s!functional!
outcome! and! ability! to! live! independently! (Green,! 2006).! Negative! and! cognitive! aspects! of! schizoS
phrenia! often! develop! prior! to! the! onset! of! the! first! episode,! and! are! less! successfully! treated! with!
antipsychotic!drug!(APD)!therapy!(Schenkel!and!Silverstein,!2004;!Tandon!et!al.,!2010).!!
!
In!addition!to!the!unique!combination!of!symptoms!in!every!case!of!schizophrenia,!patients!commonS
ly!exhibit!characteristics!that!overlap!with!symptoms!of!other!closely!related!neuropsychiatric!disorS
ders,! including! bipolar! disorder! and! major! depression! (Rothschild,! 2013).! This! overlap! includes!
symptoms! such! as! psychotic! features,! mood! dysregulation! and! cognitive! deficits! (Lee,! SH! and! the!
CrossSDisorder! Group! of! the! Psychiatric! Genomics! Consortium,! 2013),! although! the! disorders! also!
have! distinct! molecular! underpinnings,! consequently! resulting! in! some! phenotypic! distinctions! and!
separate!diagnostic!classification!and!treatment!in!the!clinic!(Buckley!et!al.,!2009;!Rothschild,!2013).!
Yet! the! sometimesSblurred! diagnostic! boundaries,! in! combination! with! the! heterogeneous! and! dyS
namic! symptom! profile,! render! schizophrenia! a! complex! disorder! to! characterise! and! ultimately!
treat.!It!is!thus!fundamental!to!decode!which!molecular!alterations!underpin!each!specific!symptom,!
as! this! has! critical! implications! for! advising! the! use! of! pharmacotherapies! (DeRubeis! et! al.,! 2014;!
Mirzakhanian!et!al.,!2014).!
!

1.1.2! The!genetic!underpinnings!of!schizophrenia!
Although!several!common!genetic!variations!have!been!associated!with!the!aetiology!schizophrenia,!
the!type!and!number!of!genes!involved!remain!unclear!(Ripke!et!al.,!2013).!!A!large!number!of!genetic!
studies! have! been! undertaken! in! schizophrenia! caseScontrol! populations,! including! candidate! gene!
approaches,! gene! expression! analyses,! linkage! analyses! and! genomeSwide! association! studies! (e.g.!
Andreassen!et!al.,!2014;!Crowley!et!al.,!2013;!McCarroll!et!al.,!2014;!Modinos!et!al.,!2013;!Ripke!et!al.,!
2013).!It!has!been!particularly!challenging!to!define!a!clear!number!of!genes!and!markers!involved!in!
schizophrenia,!mainly!owing!to!the!heterogeneity!of!the!schizophrenia!patients!in!the!tested!populaS
tions.!Nonetheless,!the!contribution!of!genetic!variation!in!the!emergence!of!schizophrenia!has!been!
well!established!and!is!widely!accepted.!
!
The! strongest! evidence! in! support! of! a! genetic! susceptibility! to! schizophrenia! stems! from! the! first!
familial!studies!(Kendler!and!Diehl,!1993).!Approximately!10%!of!patients!with!schizophrenia!have!a!
firstSdegree! relative! also! affected! by! the! disorder! (Cardno! and! Gottesman,! 2000;! Gottesman! et! al.,!
1976),!with!the!prevalence!being!10!times!higher!in!biological!relatives!compared!to!adoptees!with!
schizophrenia!(Kety,!1987;!Kety!et!al.,!1994).!Reports!from!twin!studies!suggest!that!the!incidence!of!
schizophrenia! is! significantly! higher! in! monozygotic! (31%)! compared! to! dizygotic! (7%)! twins,! and!
the!concordance!rate!in!monozygotic!twins!is!approximately!75S91%!(Kendler!and!Robinette,!1983).!!
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Over! twenty! genomeSwide! association! studies! have! investigated! the! location! of! genes! that! may! be!
involved!in!the!emergence!of!schizophrenia.!MetaSanalyses!of!these!investigations!have!suggested!the!
consistent!involvement!of!particular!loci,!with!several!candidate!genes!identified!through!systematic!
fine!mapping,!linkage!analysis,!and!SNP!analysis!of!linkage!peaks!(Badner!and!Gershon,!2002;!Lewis!
et!al.,!2003).!A!multitude!of!loci!have!been!implicated,!including!1q,!2,!3p,!5q,!6p,!8p,!11q,!13q,!14q,!
20p!and!22q,!with!over!1500!SNPs!in!these!regions!being!associated!with!the!disorder!(Ripke!et!al.,!
2013).!!
!
As!highlighted!by!these!studies,!schizophrenia!cannot!be!defined!by!one!sole!genetic!origin,!which!is!
reflected!by!the!inherent!complexity!of!the!disorder.!Attempts!to!identify!associated!genes!have!been!
limited,!due!to!factors!including!variable!diagnostic!boundaries,!heterogeneity,!comorbidity!and!polS
ygenic! nonSMendelian! inheritance! patterns! (Cloninger,! 1994).! However,! molecular! genetics! remain!
an!important!component!in!classifying!the!spectrum!of!the!clinical!phenotype!(Ayalew!et!al.,!2012),!
and!may!also!have!an!important!impact!on!psychopharmacology!(Harrison,!2013).!Some!clinical!feaS
tures! can! already! be! correlated! with! specific! genetic! variance! or! mutations,! and! therefore! genetic!
studies!provide!a!way!to!improve!nosology!and!move!towards!individualised!treatment!approaches!
(Ayalew!et!al.,!2012;!Harrison,!2013).!
!

1.1.3! The!molecular!neurobiology!of!schizophrenia!
Whilst!it!has!been!established!that!multiple!genetic!factors!are!involved!in!the!emergence!of!schizoS
phrenia,!a!consistent!understanding!of!how!genetic!variations!may!lead!to!specific!symptoms!is!lackS
ing.!However!with!evidence!from!behavioural!animal!and!human!studies,!it!has!become!clear!that!alS
tered!psychiatricSlike!behaviours!(e.g.!hyperlocomotion,!prepulse!inhibition,!social!interaction!in!anS
imals,! and! hallucinations,! delusions,! social! withdrawal! in! humans)! are! reflective! of! alterations! in!
many! neurotransmitter! systems,! such! as! the! dopaminergic,! glutamatergic,! GABAergic,! and! serotoS
ninergic!systems,!among!more!(Deng!and!Dean,!2013).!It!is!likely!that!core!alterations!to!one!system!
causes!a!cascade!of!events!that!lead!to!globally!altered!neurotransmission!in!the!majority!(if!not!all)!
neurotransmitter! systems,! attributable! to! the! close! interplay! of! neurotransmitter! systems! in! both!
time! and! space.! Researchers! have! therefore! searched! for! the! cause! of! this! “domino! effect”.! Of! these!
many!studies,!it!has!been!repeatedly!hypothesised!that!core!alterations!might!originate!within!dopaS
mine!and!glutamate!signalling.!Signalling!via!these!neurotransmitters!have!been!strongly!linked!with!
the! pathophysiology! of! schizophrenia,! and! are! arguably! amongst! the! leading! theories! defining! the!
underlying! molecular! neurobiology! of! schizophrenia! and! manifestation! of! the! related! phenotype!
(Deng!and!Dean,!2013).!
!
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The!dopaminergic!system!was!the!first!to!be!implicated!in!the!pathology!of!schizophrenia,!and!an!imS
balance! in! dopaminergic! neurotransmission! has! been! well! documented! (Toda! and! AbiSDargham,!
2007).! Dopamine! is! a! monoamine! neurotransmitter! that! controls! fast! glutamate! and! gammaS
aminobutyric! acid! (GABA)! neurotransmission! via! GSprotein! coupled! dopamine! receptors! (Toda! and!
AbiSDargham,!2007).!Accumulated!evidence!for!a!role!of!dopamine!in!schizophrenia!includes!the!abilS
ity!of!dopamine!reuptake!inhibitors!to!induce!hallucinations!and!delusions!analogous!to!the!positive!
symptom!profile!of!schizophrenia!(Matthysse,!1974),!and!therapeutic!efficacy!of!dopamine!D2!recepS
tor!antagonists!against!hallucinations!and!delusions!(Andersson!et!al.,!1998).!Yet,!dysfunctions!of!the!
dopaminergic!system!do!not!absolutely!account!for!cognitive!symptoms!which!are!arguably!the!more!
discreet!and!debilitating!aspects!of!the!disorder.!Alterations!to!glutamatergic!signalling!has!become!
increasingly! implicated! in! the! emergence! of! these! symptoms,! particularly! cognitive! deficits!
(Moghaddam!and!Javitt,!2011).!Hence,!in!recent!years,!the!glutamatergic!theory!of!schizophrenia!has!
gained! traction,! and! many! researchers! are! focusing! efforts! on! the! development! of! drugs! that! target!
the! glutamate! system,! with! a! focus! on! addressing! the! cognitive! deficits! (Moghaddam! and! Javitt,!
2011).!
!

1.1.3.1)Glutamate)and)the)glutamatergic)hypothesis)of)schizophrenia)
Glutamate! is! the! principal! excitatory! neurotransmitter! present! in! the! majority! of! synapses! in! the!
brain.!It!exerts!its!excitatory!effects!through!a!number!of!receptors!classified!into!two!groups:!ionoS
tropic!and!metabotropic!receptors.!Ionotropic!glutamate!receptors!(iGluRs),!which!include!NSmethylS
DSaspartate!receptors!(NMDAR),!alphaSaminoS3ShydroxyS5SmethylS4Sisoxazole!propionic!acid!recepS
tors!(AMPAR)!and!kainate!receptors,!are!ligandSgated!ion!channels!(Goff!and!Wine,!1997).!ConverseS
ly,! metabotropic! glutamate! receptors! (mGluR)! are! GSproteinScoupled! receptors! (GPCRs).! Eight!
mGluRs!(mGluR1S8)!have!been!discovered!and!cloned!thus!far,!and!are!grouped!into!three!categories:!
Group!1!(mGluR1!and!5),!Group!2!(mGluR2!and!3)!and!Group!3!(mGluR4,!6,!7!and!8)!according!to!seS
quence!homology,!pharmacological!properties!and!downstream!activations!(Nicoletti!et!al.,!2011).!!!!
!
Glutamate!is!vital!to!neurodevelopment,!as!well!as!synapse!organisation!and!sensorimotor!gating!in!
adults! (Arnold! et! al.,! 2005).! Glutamate! has! been! linked! to! many! processes! involved! in! cognition,!
memory,!pain!and!perception!(Bleakman!et!al.,!2006;!Robbins!and!Murphy,!2006).!Almost!every!exS
citatory! neuron! in! the! brain! is! glutamatergic,! which! is! extremely! important! considering! excessive!
concentrations!of!glutamate!are!neurotoxic,!and!understimulation!of!glutamatergic!receptors!can!disS
rupt!a!multitude!of!processes!in!the!brain!responsible!for!cell!survival!and!plasticity.!It!is!thus!imperS
ative!that!the!glutamate!system!is!properly!regulated,!as!altered!modulation!can!lead!to!cell!death!or!
neuronal!dysfunction,!and!ultimately!neuropsychiatric!diseases!such!as!schizophrenia!(Moghaddam!
and!Javitt,!2011;!Sanacora!et!al.,!2012).!
!
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Glutamatergic!hypofunction!in!schizophrenia!was!first!proposed!in!1980!by!Kim!and!colleagues!as!a!
result! of! low! levels! of! glutamate! cerebrospinal! fluid! of! individuals! with! schizophrenia! (Kim! et! al.,!
1980).!After!several!decades!of!further!investigations,!the!resulting!glutamate!hypothesis!of!schizoS
phrenia!provides!a!useful!framework!to!delineate!the!complexities!of!schizophrenia,!as!it!largely!acS
counts! for! the! neurotransmitter! alterations! that! have! been! reported! in! schizophrenia,! and! subseS
quent!symptom!profiles!(positive,!negative!and!cognitive)!(Moghaddam!and!Javitt,!2011).!Specifically,!
hypofunction!of!glutamatergic!NMDARs!results!in!a!cascade!of!molecular!alterations!that!contribute!
to!psychosis!and!other!aspects!of!schizophrenia!symptomatology.!This!is!supported!by!the!action!of!
NMDAR!antagonists,!which!precipitate!positive,!negative!and!cognitive!schizophreniaSlike!symptoms!
in!humans!and!animals!(Chartoff!et!al.,!2005;!Olney!et!al.,!1999),!and!exacerbates!preSexisting!sympS
toms!in!schizophrenia!subjects!(Javitt!and!Zukin,!1991).!In!addition,!adjunct!treatment!of!schizophreS
nia!patients!with!glycine!or!cycloserine!(coSagonists!of!the!NMDAR)!has!been!shown!by!some!studies!
to! improve! schizophrenia! symptoms,! including! the! negative! and! cognitive! deficits! (Lin! et! al.,! 2011;!
Singh!and!Singh,!2011).!Extensive!molecular!evidence!of!NMDAR!hypofunction!has!also!been!reportS
ed! in! by! many! groups! utilising! the! postmortem! schizophrenia! brain,! although! nearly! as! many! have!
detected!no!change!(Hu!et!al.,!2014).!While!it!cannot!be!concluded!from!these!studies!that!a!primary!
deficit!in!the!NMDAR!is!solely!responsible!for!the!aetiology!of!schizophrenia,!these!studies!highlight!
that!dysfunction!of!glutamatergic!signalling,!likely!via!NMDAR!dysfunction,!greatly!contributes!to!the!
pathology!of!schizophrenia!(Kantrowitz!and!Javitt,!2010).!
!

1.1.4! Metabotropic!glutamate!receptor!5!
1.1.4.1)mGluR5)distribution)and)structure)
Although!several!lines!of!evidence!support!the!involvement!of!the!NMDAR!in!glutamatergic!dysfuncS
tion!associated!with!schizophrenia,!it!is!unlikely!that!it!is!the!solitary!aetiological!factor.!Several!studS
ies!have!reported!no!changes!in!NMDARs!in!the!schizophrenia!brain!(see!Hu!et!al.,!2014)!and!glycine!
agonists! have! been! unsuccessful! in! some! populations! (Singh! and! Singh,! 2011),! suggesting! NMDAR!
hypofunction!may!be!specific!to!a!population!of!schizophrenia!subjects.!mGluR!networks!dynamically!
modulate!fastSsignalling!iGluRs!in!synchronisation!with!signalling!demands.!This!modulation!is!critiS
cal!for!efficient!glutamate!signalling!and!the!prevention!of!excitotoxicity.!It!is!thus!possible!that!dysS
function!within!this!aspect!of!the!glutamate!system!may!also!exist,!which!contributes!to!the!glutamaS
tergic! dysfunction! observed! in! the! disorder! (Newell! et! al.,! 2014).! In! particular,! Groups! 1! and! 2!
mGluRs!are!currently!under!scrutiny!in!relation!to!schizophrenia,!although!unique!interconnections!
between!the!NMDAR!and!mGluR5!cause!this!glutamate!receptor!subtype!to!be!of!special!interest!(see!
section!1.1.4.2).!
!
Unlike!Group!2!mGluRs,!which!are!predominately!expressed!on!the!presynaptic!membrane!and!modS
ulate! glutamate! release,! Group! 1! mGluRs! are! most! prevalently! expressed! on! the! postS! and! periS
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synaptic! neuronal! membrane! (Lujan! et! al.,! 1996)! where! they! encircle! and! regulate! a! core! of! fastS
signalling! NMDARs! (Nusser! et! al.,! 1994).! Although! mGluR1! shares! similar! sequence! homology! and!
protein!interactions!with!mGluR5,!the!latter!is!of!particular!interest.!mGluR5!is!abundantly!expressed!
on! cortical,! hippocampal! and! striatal! neurons! (Abe! et! al.,! 1992;! Masu! et! al.,! 1991;! Prezeau! et! al.,!
1994).!The!increased!distribution!of!mGluR5!in!these!particular!brain!regions!(which!are!highly!inS
volved!in!schizophrenia!pathophysiology)!is!notable:!firstly,!this!may!be!indicative!of!involvement!of!
mGluR5!in!the!pathophysiology!of!schizophrenia,!considering!mGluR5!is!highly!expressed!in!regions!
vastly! reported! to! have! altered! function! in! the! disorder! such! as! the! PFC! and! hippocampal! regions;!
secondly,! it! renders! mGluR5! a! particularly! valuable! target! with! regards! to! the! treatment! of! schizoS
phrenia,!as!it!allows!more!specified!correction!of!glutamatergic!dysfunction!rather!than!a!global!effect!
which!currently!limits!many!preclinical!glutamatergicSbased!drugs!(Newell,!2013).!mGluR5!also!has!a!
favourably!distinct!interaction!with!the!NMDAR!(Pietraszek!et!al.,!2005),!and!is!able!to!modulate!the!
response!of!other!neurotransmitters!including!dopamine!and!GABA!(Bordi!and!Ugolini,!1999;!Mohn!
et!al.,!1999;!Olney!and!Farber,!1995).!!
!
mGluR5!consists!of!a!large!NSterminal!containing!an!agonistSbinding!VenusSflyStrap!domain,!joined!to!
the! 7Stransmembrane! domain! by! a! conserved! cysteine! rich! chain! (Francesconi! and! Duvoisin,! 1998;!
Rondard!et!al.,!2006)!(Figure!1.1).!The!7Stransmembrane!domain!is!also!partly!responsible!for!activaS
tion!of!the!coupled!GSprotein!(Niswender!and!Conn,!2010).!The!cytoplasmic!tail!of!mGluR5!extends!
intracellularly,! and! contains! binding! motifs! for! many! interacting! proteins! that! regulate! its! function!
and!localisation.!This!region!is!also!important!for!GSprotein!coupling!(Mary!et!al.,!1998;!Prezeau!et!al.,!
1996),!which!ultimately!regulates!intracellular!second!messengers.!
!

!
Figure! 1.1! mGluR5! structure.! mGluR5! consists! of! an! extracellular! venus! fly! trap! domain,! linked! to! a! seven!
transmembrane!domain!by!a!highly!conserved!cysteine!rich!domain,!and!a!long!cytoplasmic!carboxyl!tail.!

!

Natalie!Matosin!!

!

22!

!
The! Venus! fly! trap! domain! (or! NSterminus)! is! the! site! of! agonist! binding,! as! well! as! having! dimerS
forming! properties! (Parnot! and! Kobilka,! 2004).! Accumulating! evidence! supports! the! existence! and!
importance! of! class! C! GPCR! homo! and! heterodimers,! joined! at! the! NStermini! by! disulphide! bonds!
(Doumazane!et!al.,!2011;!Figure!1.2a).!Dimerisation!is!hypothesised!to!play!a!key!role!in!mGluR5!actiS
vation,!and!dimer!arrangement!may!be!critical!to!mGluR5/GSprotein!coupling!(Kniazeff!et!al.,!2004;!
Tateyama! and! Kubo,! 2007).! Regarding! dimer! synthesis,! it! is! hypothesised! that! GPCR! dimers! are!
formed! intracellularly! soon! after! biosynthesis,! and! trafficked! or! internalised! as! a! dimeric! complex;!
however,!it!is!unclear!whether!these!dimers!are!permanent!structures!(Parnot!and!Kobilka,!2004),!if!
they!are!dynamically!regulated!(break!apart!and!reform)!at!the!cellSsurface!(Milligan,!2004),!or!which!
molecules!are!responsible!for!the!synthesis!or!regulation!of!these!dimers.!Considering!mGluR5!is!reS
ported!to!only!be!functional!in!a!dimer!complex!(El!Moustaine!et!al.,!2012;!Romano!et!al.,!1996),!dyS
namic!regulation!of!the!dimer!might!act!as!a!strategy!to!reduce!mGluR5!function!in!situations!of!overS
stimulation.!Thus,!the!overall!knowledge!regarding!mGluR5!dimers!is!limited,!and!additional!“chapS
eroning”Stype!molecules,!that!may!play!a!role!in!mGluR5!dimer!regulation,!are!unknown.!
!
Beyond! extracellular! activation,! mGluR5! endogenous! interactions! predominately! take! place! at! the!
intracellular!cytoplasmic!tail,!which!is!distinctive!between!the!three!mGluR5!splice!variants!(Figure!
1.2b).!mGluR5a!is!highly!expressed!in!the!postnatal!rat!brain!and!therefore!thought!to!be!involved!in!
early! development! (Minakami! et! al.,! 1995).! mGluR5b! differs! to! mGluR5a! as! it! contains! a! 32! amino!
acid!insertion!(Romano!et!al.,!1996).!Conversely,!mGluR5d,!with!a!267!amino!acid!shorter!CSterminus!
that!mGluR5a!(Malherbe!et!al.,!2002).!Insofar,!our!knowledge!regarding!the!functional!differences!in!
these!mGluR5!splice!variants!is!limited.!mGluR5b!is!reportedly!more!highly!expressed!than!mGluR5a!
in!the!adult!brain!(Malherbe!et!al.,!2002);!however,!mGluR5!splicing!may!vary!in!specific!cell!types,!
such! as! in! the! case! of! mGluR1! (Pin! et! al.,! 1992).! Although! the! pharmacological! profiles! of! mGluR5a!
and! mGluR5b! do! not! appear! to! differ! (Mion! et! al.,! 2001),! mGluR5a! and! mGluR5b! were! reported! to!
have! opposing! functions! in! one! study:! mGluR5a! was! shown! to! supress! neuronal! maturation,! while!
mGluR5b!encouraged!neurite!growth!and!expansion!in!a!neuroblastoma!cell!line!(Mion!et!al.,!2001).!
This!suggests!that!synchronised!function!of!these!splices!is!essential!for!healthy!brain!development.!
There!are!no!reports!of!how!mGluR5d!splice!function!differs!to!mGluR5a/b!or!its!role!during!develS
opment.! However,! the! shorter! CSterminus! suggests! differential! downstream! interactions! and! effecS
tors!(Table!1),!but!this!remains!to!be!experimentally!confirmed.!Notably,!due!to!the!close!sequence!
homology!it!is!currently!not!possible!to!experimentally!distinguish!between!protein!expression!of!the!
mGluR5!splice!variants,!thus!limiting!the!ability!to!determine!functional/expressional!differences!of!
these!splices!at!the!protein!level.!
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Figure!1.2!Dimerisation!and!splice!variants!of!mGluR5.!(a) Schematic representation of mGluR5 dimerisa-

tion. mGluR5 is reported to form homodimer and heterodimer complexes, by the formation of disulphide
bonds between the extracellular VFTDs with other mGluR5s, or structurally similar GPCR such as
mGluR51a, adenosine or GABA-B receptors (Doumazane et al., 2011; Fuxe et al., 2008; Romano et al.,
1996). (b) Schematic representation of the three known mGluR5 splice variants, mGluR5a, mGluR5b and
mGluR5d, which have different length c-termini.!
!
!

1.1.4.2)mGluR5)signalling)pathways)
Studies!spanning!over!25!years!have!elucidated!numerous!details!regarding!mGluR5!pathways,!effecS
tors!and!interactions.!The!mGluR5!pathway!is!summarised!in!Figure!1.3.!!
!
mGluR5!and!NMDAR!are!physically!linked!by!the!scaffolding!proteins!Homer,!SH3!and!multiple!ankyrS
in!repeat!domains!(SHANK),!guanylateSkinaseSassociated!protein!(GKAP,!also!known!as!SAPAP)!and!
postSsynaptic! density! 95! (PSDS95)(Tu! et! al.,! 1999).! This! link! is! modulated! by! the! multiscaffolding!
proteins! Tamalin! and! Preso1! (Hu! et! al.,! 2012;! Kitano! et! al.,! 2002).! These! scaffolds! also! connect!
mGluR5!to!intracellular!inositol!1,4,5Striphosphate!(IP3)!receptors!expressed!on!the!endoplasmic!reS
ticulum,!and!couple!mGluR5!to!the!mammalian!target!of!rapomycin!(mTOR)!pathway!via!protein!kiS
nase!B!(Akt)!and!PI3!Kinase!and!its!enhancer!(PI3K/PIKE)!(Page!et!al.,!2006).!Binding!of!glutamate!to!
mGluR5!activates!the!GSprotein!Gq,!subsequently!activating!phospholipase!C!(PLC);!PLC!initiates!conS
version! of! phosphoinositide! (PI)! to! IP3! as! well! as! activation! of! diacylglycerol! (DAG).! IP3! also! causes!
release!of!intracellular!calcium!from!the!endoplasmic!reticulum.!The!combination!of!DAG!with!intraS
cellular! calcium! release! (which! also! occurs! due! to! NMDAR! activation),! initiates! phosphorylation! of!
proteinSkinase! C! (PKC)! (Skeberdis! et! al.,! 2001).! PKC! signalling! results! in! downstream! activation! of!
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cAMP!response!elementSbinding!(CREB),!brainSderived!neurotrophic!factor!(BDNF),!prolineSrich!tyS
rosine!kinase/cell!adhesion!kinase!ß!(Pyk2/CAKß)!and!Src!protein;!in!turn,!Src!directly!potentiates!
the!NMDAR!and!calcium!dependant!protein!phosphatase!2B/calcineurin!(PP2B/CaN)!(Ali!and!Salter,!
2001;! Groveman! et! al.,! 2012).! Lastly,! Norbin! modulates! mGluR5! signalling! and! cell! surface! expresS
sion,!and!potentiates!the!release!of!intracellular!calcium!downstream!(Wang!et!al.,!2009).!
!
mGluR5!downstream!signalling!molecules!play!an!important!role!in!cell!homeostasis!and!regulation!
of!neuronal!function.!For!example,!(i)!CREB!binds!to!DNA!sequences!to!induce!or!reduce!transcripS
tion!factors!for!many!genes!such!as!BDNF!(Carlezon!Jr!et!al.,!2005),!(ii)!the!neurotrophic!factor!BDNF!
promotes! the! survival,! growth! and! differentiation! of! new! neurons! (Acheson! et! al.,! 1994),! and! (iii)!
mTOR!modulates!cell!growth,!proliferation,!motility,!survival,!as!well!as!protein!synthesis!and!tranS
scription!(Hay!and!Sonenberg,!2004).!Via!activation!of!these!signalling!molecules,!mGluR5!is!also!inS
volved! in! regulating! many! processes! involving! synaptic! plasticity! (Vinson! and! Conn,! 2012),! such! as!
memory,!cognition,!pain!and!movement!(Ayala!et!al.,!2009;!Ménard!and!Quirion,!2012;!Radulovic!and!
Tronson,!2012;!Samadi!et!al.,!2008).!In!accordance,!mGluR5!pathways!are!implicated!in!many!pathoS
logical! states! where! alterations! to! these! downstream! pathways! has! been! reported,! such! as! schizoS
phrenia,!depression,!bipolar!disorder,!Alzheimer’s!disease,!Parkinson’s!disease,!and!pain!syndromes!
(Angelucci!et!al.,!2005;!Carlezon!Jr!et!al.,!2005;!Gururajan!and!Buuse,!2014).!!
!

!
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Figure!1.3!Schematic!of!mGluR5!signalling!pathway,!in!the!context!of!the!NMDAR.!GlutamateScontaining!
vesicles!are!exocytosed!into!the!synaptic!cleft,!and!glutamate!binds!to!both!mGluR5!and!NMDAR.!ExtraScellular!
calcium!ion!influx!occurs!through!phosphorylated!NMDAR!ion!channel!and!triggers!further!release!of!calcium!
from!intracellular!stores.!Binding!of!glutamate!to!mGluR5!activates!Gq,!subsequently!activating!PLC.!PLC!initiS
ates!conversion!of!phosphoinositide!to!IP3!and!subsequent!activation!of!DAG,!and!release!of!intracellular!calciS
um!from!the!ER.!Scaffold!proteins!(Homer,!SHANK,!GKAP!and!PSD95)!physically!link!mGluR5!and!NMDAR,!
modulated!by!Tamalin!and!Preso1,!which!also!connect!mGluR5!to!intracellular!IP3!receptors!expressed!on!the!
endoplasmic!reticulum.!mGluR5!signals!via!PKC!and!mTOR!pathways.!Lastly,!Norbin!binds!directly!to!the!CS
terminus!of!mGluR5!where!it!positively!modulates!mGluR5!signalling!and!cell!surface!expression,!and!inhibits!
the!release!of!intracellular!calcium!downstream.!!
Abbreviations:!Akt:!protein!kinase!B,!BDNF:!brain!derived!neurotrophic!factor,!CaN:!calcineurin,!ecCa2+:!extraS
cellular!calcium,!icCa2+:!intracellular!calcium,!CREB:!cAMP!response!element!binding!protein,!DAG:!diacyl!glycS
erol,!ER:!endoplasmic!reticulum,!GKAP:!guanylateSkinaseSassociated!protein,!Gq:!guanosine!nucleotideSbinding!
protein!q,!IP3:!inositol!triphosphate,!mTOR:!mammalian!target!of!rapamycin,!Norbin:!neurochondrin,!PIKE:!
PI3K!enhancer,!PI:!inositol!monophosphate,!PI3K:!PI3!kinase,!PKC:!protein!kinase!C,!PLC:!protein!lipase!C,!PreS
so1:!FRMPD4,!PSD95:!postSsynaptic!density!95,!Pyk2:!protein!tyrosine!kinase!2,!SHANK:!SH3!and!multiple!
ankyrin!repeat!domains,!Src:!ProtoSoncogene!tyrosineSprotein!kinase,!Tamalin:!GRASP1!
!
!

1.1.4.3)mGluR5)G6protein)independent)pathways)and)endogenous)regulation)
Like! most! GPCRs,! mGluR5! activation! is! modulated! by! phosphorylation.! Enzymatic! activity! at! the!
mGluR5!phosphorylation!sites!is!a!major!process!in!regulation!of!mGluR5!signalling,!localisation!and!
function! (Mao! et! al.,! 2008).! However,! in! addition! to! enzymatic! modulators,! GSprotein! independent!
pathways!also!modulate!the!mGluR5!cellular!response!(Heuss!et!al.,!1999).!mGluR5!intracellular!doS
mains! are! coupled! to! a! multitude! of! endogenous! molecules! that! modulate! mGluR5! trafficking,! cellS
surface! expression,! proteinSprotein! couplings! and! internalisation! (Table! 1.1).! These! endogenous!
molecules! may! also! have! additional! chaperoning! roles,! involving! postStranslational! protein! folding,!
trafficking! between! cellular! machinery,! and! tagging! mutant! proteins! for! degradation! (Ellis! and! Van!
der!Vies,!1991;!Hartl,!1996);!however,!virtually!nothing!is!known!regarding!these!processes!in!relaS
tion!to!mGluR5.!
!
Table!1.1!Summary!of!endogenous!molecules!that!interact!with!the!intracellular!tail!of!mGluR5!(Adapted!
from!Enz,!2007).!
Modulating!protein!

mGluR5!isoform!

!
CaIN!

!
mGluR5a!

Interacting!Region!

Reference!

GRK!2/3!

!
657S727,!
distal!
CS
terminus! (exact! residue!
unknown)!
mGluR5!
Unknown! if! binds! to! CS
terminus!
region1:! mGluR5a/b/d;! region! 1:! 842S869;! reS
region!2:!mGluR5a/b!
gion!2:!890S918!
mGluR5a/b/d!
840!

Homer1a!

mGluR5a/b/d!

1171S1180!

Homer1b/c!

mGluR5a/b!

1133S1138!

Norbin!

region! 1:! mGluR5a/b/d,! region! 1:! 857S867;! reS
region! 2:! mGluR5a/b! gion!2:!893S903!
only!

Calcineurin!
Calmodulin!
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(Ferreira!et!al.,!2009)!

(Alagarsamy! et! al.,!
2005)!
(Minakami!et!al.,!1997)!
(Sorensen! and! Conn,!
2003)!
(Brakeman!et!al.,!1997)!
(Brakeman! et! al.,! 1997;!
Tu!et!al.,!1999)!
(Wang!et!al.,!2009)!
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Optineurin!

mGluR5a!

828S1180!

(Anborgh!et!al.,!2005)!

PP1!gamma!1!

mGluR5a/b!

881S885!

(Croci!et!al.,!2003)!

Preso1!

mGluR5a/b!

986S974!

(Hu!et!al.,!2012)!

SiahS1A!

mGluR5a/b!

893S919!

(Ishikawa!et!al.,!1999)!

SiahS1A!

mGluR1a/b!

Tamalin!

mGluR5a/b/d!

region! 1:! 905S932! (Ishikawa!et!al.,!1999)!
region!2:!893S919!
1176S1180!
(Kitano!et!al.,!2002)!

Abbreviations:! CaIN,! calcinuerin! inhibitior! protein;! GRK,! GSprotein! regulatory! kinase;! PP1,! protein! phosphaS
tase!1;!Siah1,!seven!in!absentia!homolog!1.!

!
The!Homer1!scaffold!protein!was!the!first!discovered!modulator!of!mGluR5!(Brakeman!et!al.,!1997).!
Homer1!proteins!plays!a!critical!role!in!organisation!of!the!postsynaptic!density!and!are!reported!as!
altered! in! patients! with! schizophrenia! (total! isoforms;! Engmann! et! al.,! 2011).! Additionally,! genetic!
variation!in!the!HOMER1!gene!has!been!significantly!associated!with!schizophrenia!(Spellman!et!al.,!
2011).!In!support,!genetic!abolition!of!Homer1!(total!isoforms)!produces!strong!schizophrenia!pheS
notypical!behaviours!in!mice!(Jaubert!et!al.,!2007).!Disruption!to!Homer1/mGluR5!linkages!have!also!
been! recently! demonstrated! in! an! acute! and! chronic! stressSinduced! model! of! psychiatric! disorder!
(Wagner!et!al.,!2013;!Wagner!et!al.,!2015).!A!role!of!Homer1!in!the!modulation!of!mGluR5!and!schizoS
phrenia! has! thus! been! established;! however,! Homer! is! only! one! of! many! mGluR5Sinteracting! moleS
cules.!
!
The!importance,!role!and!function!of!other!mGluR5!endogenous!interacting!partners!has!gained!tracS
tion!with!many!basic!science!researchers,!such!as!the!Enz!group!(Enz,!2007).!Through!their!work!and!
others,!it!is!clear!that!certain!molecules!are!modulators!of!mGluR5!activity!and!localisation.!In!some!
instances,!this!has!been!experimentally!confirmed,!as!alterations!to!the!expression!of!these!modulaS
tors! in! animals! can! induce! schizophreniaSlike! behaviours! (e.g.! Homer1:! Szumlinski! et! al.,! 2005;!
Norbin:! Wang! et! al.,! 2009).! Considering! that! mGluR5! activity! and/or! signalling! might! be! impaired!
should!these!signalling!partners!be!altered,!it!is!crucial!to!consider!these!mGluR5Sinteracting!proteins!
in!the!context!of!schizophrenia!and!other!pathological!states.!However!to!date,!many!of!these!moleS
cules! remain! unstudied! in! animal! models,! and! virtually! unstudied! in! human! tissues! of! pathological!
conditions,!including!neuropsychiatric!disorder.!
!
Of!the!endogenous!proteins!that!modulate!mGluR5!(Table!1.1),!Norbin!(neurochondrinS1)!(Wang!et!
al.,! 2009),! Tamalin! (GRPS1Sassociated! scaffold! protein! or! GRASP)! (Kitano! et! al.,! 2002)! and! Preso1!
(FERM!and!PDZ!domainScontaining!protein!4!or!FRMPD4)!(Hu!et!al.,!2012)!are!particularly!distincS
tive! modulators! of! mGluR5! signalling,! desensitisation/internalisation! and! trafficking/localisation.!
Despite!that!some!information!regarding!their!biological!roles!has!been!uncovered,!they!remain!unS
studied!in!the!postmortem!schizophrenia!brain,!and!largely!unstudied!in!any!schizophreniaSrelevant!
paradigm.!
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1.1.4.3.1)

mGluR5)modulation)by)Norbin)

Norbin,!also!known!as!neurochondrinS1,!is!a!75kDa!cytoplasmic!protein!expressed!mainly!in!the!cenS
tral! nervous! system.! The! overexpression! of! Norbin! in! neuronal! cultures! resulted! in! neurite! outS
growth,! suggesting! Norbin! plays! an! important! role! in! neuronal! plasticity! (Mochizuki! et! al.,! 1999;!
Shinozaki! et! al.,! 1997).! Total! deletion! of! Norbin! leads! to! embryonic! death! 3.5! to! 6.5! days! following!
conception,!suggesting!Norbin!plays!a!crucial!role!in!neuronal!development!(Mochizuki!et!al.,!1999).!
Norbin!has!been!found!to!interact!with!a!number!of!membraneSbound!proteins,!such!as!transmemS
brane!semaphorin!Sema4C,!melaninSconcentrating!hormone!receptor!1,!and!group!I!mGluRs!(Wang!
et!al.,!2010).!Notably,!these!receptors!modulate!calcium!influx,!suggesting!that!Norbin!plays!a!critical!
role!in!modulating!neuronal!excitability!and!signalling.!
!
Specifically,!Norbin!was!reported!to!closely!modulate!mGluR5!signalling!and!cellSsurface!localisation!
(Wang! et! al.,! 2009).! Overexpression! of! Norbin! in! primary! cortical! neurons! was! shown! to! increase!
mGluR5!cellSsurface!expression,!whilst!in!cultures!with!depleted!Norbin,!mGluR5!cellSsurface!expresS
sion!was!reduced!(Wang!et!al.,!2009).!Conditional!cortical!Norbin!knockout!mice!also!display!schizoS
phreniaSlike! phenotypic! behaviours,! such! as! altered! sensorimotor! gating,! psychotomimeticSinduced!
hyperlocomotion,!deficits!in!hippocampal!synaptic!plasticity,!as!well!as!reduced!mGluR5!cell!surface!
expression! (Wang! et! al.,! 2009).! The! behavioural! profile! of! cortical! Norbin! knockout! mice! strongly!
suggests! an! important! role! for! Norbin! in! the! context! of! schizophrenia;! however! since! the! NorbS
in/mGluR5!interaction!was!reported!in!2010,!it!has!not!been!followedSup!in!a!schizophrenia!relevant!
paradigm.!
!

1.1.4.3.2)

mGluR5)modulation)by)Tamalin)

Tamalin! (also! known! as! GRIPSassociated! proteinS1! or! GRASP1)! is! a! 95kDa! PSDS95! binding! scaffold!
abundant! in! the! postSsynaptic! density! (Kitano! et! al.,! 2002).! As! a! scaffold! protein,! its! main! cellular!
function!is!to!facilitate!macromolecular!protein!complexes!by!binding!signalling!partners!through!its!
multiple!binding!motifs.!However,!Tamalin!was!also!shown!to!critically!coordinate!endosomal!pathS
ways!of!neurotransmitter!receptor!recycling,!which!is!a!process!crucial!to!synaptic!function!and!plasS
ticity! (Hoogenraad! et! al.,! 2010).! Therefore,! it! is! likely! that! Tamalin! also! plays! an! important! role! in!
learning!and!memory!processes.!
!
Tamalin!has!been!specifically!shown!to!regulate!the!cell!surface!expression!and!dendritic!targeting!of!
mGluR5,! by! binding! directly! to! the! CSterminus! of! mGluR5! (Kitano! et! al.,! 2002).! Tamalin! also! forms!
complexes! with! membraneSassociated! guanylate! kinase! invertedS2! (SSSCAM)! molecules,! which! are!
responsible!for!subcellular!trafficking,!and!it!has!thus!been!hypothesised!that!Tamalin!may!be!key!to!
proper! cellular! localisation! and! trafficking! of! mGluR5! (Kitano! et! al.,! 2003).! Since! both! mGluR5! and!
Natalie!Matosin!!

!

28!

!
Tamalin!are!reported!to!dimerise,!it!has!also!been!suggested!that!the!Tamalin!may!facilitate!mGluR5!
dimerisation,! but! this! remains! to! be! experimentally! confirmed! (Sugi! et! al.,! 2007).! Considering! that!
mGluR5!can!only!be!activated!by!an!agonist!when!in!a!dimerised!state!(Kniazeff!et!al.,!2004),!Tamalin!
may!critically!modulate!mGluR5!signalling.!Furthermore,!as!Tamalin!binds!also!to!other!scaffold!proS
teins!such!as!PSDS95!and!GKAP!(Kitano!et!al.,!2002;!Kitano!et!al.,!2003),!this!presents!the!possibility!
of! Tamalin’s! involvement! in! a! variety! of! important! proteinSprotein! interactions,! including! protein!
clustering!in!the!PSD,!and!facilitation!of!mGluR5/NMDAR!signalling.!Despite!that!the!role!of!Tamalin!
in!schizophrenia!is!largely!unknown,!one!study!reported!that!a!frameshift!within!GRM5!in!one!schizS
ophrenia!pedigree!resulted!in!disrupted!mGluR5/Tamalin!linkages!(discussed!in!section!1.5.1;!Timms!
et!al.,!2013),!providing!motive!to!further!study!the!role!of!Tamalin!in!schizophrenia!pathology.!
!

1.1.4.3.3)

mGluR5)modulation)by)Preso1)

Preso1,!encoded!by!the!FRMPD4!gene,!is!a!scaffold!protein!that!crucially!coordinates!dendritic!spine!
morphogenesis!(Mo!et!al.,!2012).!Preso1!is!comprised!of!WW,!PDZ,!and!FERM!domains,!and!is!reportS
ed!to!bind!to!PSD95!(Lee!et!al.,!2008).!More!recently,!in!a!search!for!proteins!that!bind!Homer1,!the!
multiSscaffolding!protein!Preso1!was!identified!in!addition!to!its!ability!to!bind!group!I!mGluRs!(Hu!et!
al.,! 2012).! Preso1! was! shown! to! potentiate! binding! of! proteinSdirected! kinases! (CDK5! and! ERK)! to!
mGluR5,!and!phosphorylate!the!Homer!binding!motif!of!mGluR5.!This!Preso1Sdependent!phosphoryS
lation!increases!mGluR5/Homer!binding!to!reduce!mGluR!downstream!signalling.!In!accordance,!acS
tivation!of!the!mGluR5/Preso1!complex!upSregulated!mGluR5!linkages!with!long!Homer!isoforms!(Hu!
et!al.,!2012).!Thus,!Preso1!fundamentally!modulates!mGluR5/Homer!linkages!and!mGluR5!signalling.!
As!mGluR5!linkages!to!Homer!are!critical!for!mGluR5/NMDAR!synchronisation,!Preso1!is!an!attracS
tive! novel! therapeutic! target! to! correct! potential! alterations! in! mGluR5! signalling! and! protein! couS
plings.! However! the! involvement! of! Preso1! in! the! molecular! biology! or! behavioural! phenotype! of!
schizophrenia! is! unclear,! as! to! date,! Preso1! has! only! been! studied! in! the! context! of! pain! (Hu! et! al.,!
2012;!Radulovic!and!Tronson,!2012).!
!

1.1.5! Pathological!evidence!of!mGluR5!involvement!in!schizophrenia!
1.1.5.1)Evidence)from)rodent)studies)
Investigations! of! mGluR5! knockout! mice! support! the! involvement! of! mGluR5! in! the! aetiology! of!
schizophrenia.!Deletion!of!GRM5!gene!causes!behaviours!that!are!analogous!to!behavioural!manifesS
tations! induced! by! glutamate! hypofunction! models! as! well! as! observed! schizophrenia! phenotypes,!
such! as! decreased! sensorimotor! gating,! decreased! shortSterm! spatial! memory! and! sensitivity! to! loS
comotor!deficits!induced!by!NMDAR!antagonists!(Brody!et!al.,!2003;!Chiamulera!et!al.,!2001;!Gray!et!
al.,! 2009;! Lu! et! al.,! 1997).! Furthermore,! conditional! cortical! knockout! of! mGluR5! specifically! moduS
lates!locomotor!reactivity!in!response!to!a!novel!environment,!but!does!not!affect!sensorimotor!gatS
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ing,!anxiety,!motor!coordination,!and!social!interactions,!which!are!likely!attributable!to!subcortical!
and/or!other!brain!structure!mGluR5!activity!(Jew!et!al.,!2013).!
!
In!line!with!what!has!been!observed!in!the!mGluR5!knockout!studies,!adult!rats!treated!with!mGluR5!
selective! negative! allosteric! modulators,! MPEP! (2SmethylS6S(phenylethynyl)Spyridine)! or! MTEP! (3S!
[(2SmethylS1,3SthiazolS4Syl)ethynyl]Spyridine),! displayed! social! interaction! deficits,! impaired! workS
ing! memory,! reduced! instrumental! learning,! as! well! as! intensification! of! the! detrimental! effects! inS
duced!by!NMDAR!antagonists!(Campbell!et!al.,!2004;!Henry!et!al.,!2002;!Homayoun!et!al.,!2004;!PieS
traszek! et! al.,! 2005;! Vales! et! al.,! 2010;! Vollenweider! et! al.,! 1998;! Zou! et! al.,! 2007).! Homayoun! and!
Moghaddam! (2007)! further! observed! cortical! neurons! in! the! prefrontal! cortex! (PFC)! of! awake! rats,!
where!MPEP!decreased!spontaneous!burst!activity!of!these!neurons!and!augmented!the!effects!of!the!
nonScompetitive!NMDAR!antagonist,!MKS801,!on!spontaneous!neuronal!activity.!!
!
Another!collection!of!studies!in!rodents!indicates!mGluR5!is!crucial!for!proper!cognitive!function!such!
as! learning! and! memory,! which! are! processes! disrupted! in! many! schizophrenia! patients! (Harvey,!
2013).! LongSterm! depression! (LTD)! and! longSterm! potentiation! (LTP)! are! two! opposing! neuronal!
processes!to!do!with!the!formation!and!dissociation!of!synapses,!underlying!synaptic!plasticity!in!the!
brain.!When!these!processes!are!imbalanced,!this!can!cause!deficits!in!memory!and!cognition.!DisrupS
tion!to!mGluR5!signalling!can!lead!to!imbalance!of!LTP!and!LTD!(Mukherjee!and!ManahanSVaughan,!
2013).!For!example,!mGluR5!knockout!mice!have!reduced!performance!in!NMDARSmediated!memory!
tasks!due!to!deficits!in!hippocampal!NMDARSinduced!LTP;!these!deficits!can!be!rescued!by!stimulaS
tion! of! PKC! (Jia! et! al.,! 1998).! Furthermore,! LTP! induced! by! thetaSburst! stimulation! in! hippocampal!
slices!are!impaired!by!treatment!with!MPEP!(Francesconi!et!al.,!2004;!Shalin!et!al.,!2006),!and!accordS
ingly!antagonism!of!mGluR5!in!rats!impacts!on!spatial!learning!performance!and!synaptic!plasticity,!
specifically! inhibition! of! LTP! in! CA1! and! the! dentate! gyrus! (ManahanSVaughan! and! Braunewell,!
2005).!Lastly,!the!Group!I!mGluR!agonist!DHPG!induces!LTD,!which!is!blocked!only!by!an!mGluR5!anS
tagonist,!and!is!not!present!in!mGluR5!knockout!mice!(Faas!et!al.,!2002;!Gasparini!et!al.,!1999;!Huber!
et!al.,!2001).!Notably,!a!recent!study!has!reported!that!the!cellular!location!of!mGluR5!may!impact!on!
the!exact!role!it!plays!in!synaptic!plasticity,!with!cellSsurface!expressed!mGluR5!regulating!both!LTP!
and! LTD,! whilst! intracellularly! expressed! mGluR5! modulate! LTD! only! (Purgert! et! al.,! 2014).! These!
studies!nonetheless!collectively!support!a!role!for!mGluR5!in!the!modulation!of!cognitive!functions,!
such!as!learning!and!memory.!
!

1.1.5.2)Evidence)from)genetic)studies)
GRM5)(coding!for!mGluR5;!located!at!chromosomal!region!11q14.3)!is!a!large!gene!containing!8!exS
ons! (coding! gene! region)! and! 7! introns! (nonScoding! gene! region)! that! span! over! 49,000! base! pairs!
(Devon!et!al.,!2001;!Figure!5).!A!longSrange!restriction!map!covering!the!GRM5!locus!was!previously!

Natalie!Matosin!!

!

30!

!
linked!to!schizophrenia!in!a!large!Scottish!pedigree!(Millar!et!al.,!1998).!A!novel!intragenic!microsatS
ellite!was!characterised!in!intron!6!of!GRM5!(Figure!1.4),!and!was!then!analysed!by!microsatellite!typS
ing!in!a!caseScontrol!Scottish!population!consisting!of!patients!with!schizophrenia!(n=231)!and!bipoS
lar! disorder! (n=149),! matched! with! control! subjects! (n=421).! A! significant! difference! in! allelic! freS
quency!distribution!was!reported!between!schizophrenia!cases!and!controls,!but!this!association!was!
not! apparent! in! subjects! with! bipolar! disorder! (Devon! et! al.,! 2001).! Although! this! intronic! repeat!
might!suggest!alternative!splicing!or!uncontrolled!mRNA!stability,!the!authors!further!suggested!that!
the! microsatellite! was! likely! to! be! in! linkage! disequilibrium! with! a! causative! mutation,! and! further!
studies! would! be! required! to! detect! functional! polymorphisms! associated! with! the! minor! allele! at!
197bp,!which!was!present!only!in!the!schizophrenia!cases!in!this!study!(Devon!et!al.,!2001).!
!
!

!
Figure!1.4.!Genomic!organisation!of!GRM5!located!at!11q14.3.!Exons!are!represented!by!boxes,!introns!are!
represented! between! (not! to! scale).! Microsatellite! G46931! within! intron! 7! was! previously! associated! with!
schizophrenia!in!a!caseScontrol!population!(Adapted!from!Devon!et!al.,!2001).!Abbreviations:!b=base!pair.!

!
More! recently,! GRM5! was! reported! to! be! one! of! the! top! candidate! genes! in! the! aetiology! of! schizoS
phrenia.! Using! a! convergent! functional! genomics! approach,! data! was! integrated! from! genomeSwide!
association! studies! with! available! previous! studies! from! the! postmortem! human! brain,! human! inS
duced!pluripotent!stem!cells,!human!blood!gene!expression!data,!linkage!analyses,!copy!number!variS
ation/association,!and!relevant!animal!and!cellularSbased!models!(Ayalew!et!al.,!2012).!Three!putaS
tive!SNPs!in!GRM5!were!identified!as!being!significantly!associated!with!schizophrenia!in!three!indeS
pendent!cohorts:!the!International!Schizophrenia!Consortium![rs992259,!p=0.002],!the!Genetic!AssoS
ciation! Information! Network! (GAIN)! European! American! cohort! [rs170110,! p=0.02]! and! the! GAIN!
African!American!cohort![rs1846475,!p=0.001]!(Ayalew!et!al.,!2012).!However,!no!SNP!associations!
have!been!reported!in!independent!schizophrenia!caseScontrol!populations!to!date.!
!
In! another! study,! a! range! of! techniques! (genomeSwide! array,! comparative! genomic! hybridisation,!
linkage!analysis!and!exome!sequencing)!was!performed!in!multiplex!families!with!schizophrenia,!to!
identify! genetic! factors! which! may! predispose! families! with! affected! members! to! schizophrenia!
(Timms!et!al.,!2013).!In!one!of!the!5!pedigrees!examined,!both!a!missense!(G369)!and!cis!frameshift!
mutation!(P1148fs)!was!reported!in!GRM5.!The!G369!missense,!translating!to!the!Venus!flytrap!doS
main!of!mGluR5!(corresponding!to!NSterminal!extracellular!domain),!was!hypothesised!to!affect!gluS
tamate! binding! to! mGluR5.! Alternatively,! the! cis! P1148fs! substitution! was! located! to! the! Tamalin!
binding!region!on!the!mGluR5!CSterminus.!Follow!up!coimmunoprecipitation!experiments!within!celS
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lular!assays!demonstrated!that!the!frameshift!indeed!disrupted!Tamalin!binding!to!mGluR5;!interestS
ingly,!this!appeared!to!be!specific!to!Tamalin,!as!Homer!binding!was!not!affected!even!though!Homer!
and!Tamalin!have!overlapping!binding!sites!on!mGluR5.!Furthermore,!this!disconnection!from!TamaS
lin!caused!decreased!mGluR5!surface!expression,!increased!mGluR5!internalisation!and!reduced!agoS
nistSinduced!activation!of!mGluR5!(Timms!et!al.,!2013).!
!
Whilst!these!genetic!data!directly!implicate!GRM5!in!schizophrenia!aetiology,!other!genes!that!indiS
rectly!affect!mGluR5!should!be!noted.!For!example,!several!studies!have!reported!that!RGS4!is!a!susS
ceptibility!gene!in!schizophrenia!(Large,!2007;!Shao!et!al.,!2010;!Tarazi!et!al.,!1996),!which!is!a!gene!
that! negatively! modulates! Gq! proteinSmediated! signalling,! including! that! of! mGluR5.! Furthermore,!
polymorphisms!in!HOMER1!have!also!been!associated!with!schizophrenia!in!a!Caucasian!caseScontrol!
population!(Spellmann!et!al.,!2011).!In!addition,!a!number!of!candidate!genes!differentially!involved!
in!excitatory!glutamate!signalling!have!been!associated!with!schizophrenia,!including!GRIN2B,)DISC1,!
COMT,! NRG1,! RGS4,! and! GABA6A! (Alfimova! et! al.,! 2011,! 1;! Collier! and! Li,! 2003;! Hennah! et! al.,! 2003;!
Hodgkinson!et!al.,!2004;!Li!and!He,!2006;!Liu!et!al.,!2002a;!Liu!et!al.,!2002b;!Petryshen!et!al.,!2005a;!
Petryshen!et!al.,!2005b;!Shifman!et!al.,!2002;!Weickert!et!al.,!2012).!Together,!these!studies!provide!
support! for! the! possibility! of! genetic! mutations! affecting! glutamatergic! signalling! in! schizophrenia,!
including!that!of!mGluR5.!
!

1.1.5.3)Evidence)from)human)postmortem)studies)
Whilst!the!cellular,!animal!and!genetic!studies!presented!implicate!mGluR5!and/or!its!effectors!in!the!
development! and! pathology! of! schizophrenia,! little! alteration! has! been! reported! directly! within! the!
postmortem! schizophrenia! brain! (Table! 1.2).! Several! of! these! investigations! have! analysed! mGluR5!
mRNA,!binding!and!protein!within!human!postmortem!tissues.!mGluR5!gene!expression!was!found!to!
be!unaltered!in!the!thalamus,!hippocampus,!PFC!and!striatum!of!patients!with!schizophrenia!(Fatemi!
et!al.,!2013;!Gupta!et!al.,!2005;!Ohnuma!et!al.,!2000a;!RichardsonSBurns!et!al.,!2000;!Volk!et!al.,!2010).!
Conversely,!Ohnuma!et!al.!(1998)!reported!that!mGluR5!mRNA!expression!and!glutamate!transporter!
protein! were! respectively! increased! and! decreased! in! Brodmann’s! Area! (BA)! 11,! pointing! towards!
less!functional!glutamate!and!decreased!glutamate!transmission!in!this!region.!Furthermore,!mGluR5!
mRNA!was!reported!to!be!decreased!in!the!cerebellum,!indicating!that!mGluR5!synthesis!may!be!afS
fected! in! this! region! (Fatemi! et! al.,! 2013).! It! should! therefore! be! considered! that! alterations! to!
mGluR5!gene!expression!are!brain!regionSspecific.!However!it!should!also!be!noted!that!many!of!theS
se! previous! studies! used! small! cohorts,! which! may! limit! the! interpretation! of! these! studies!
(n<20/group;!Gupta!et!al.,!2005;!Ohnuma!et!al.,!1998;!Ohnuma!et!al.,!2000b;!RichardsonSBurns!et!al.,!
2000).!
!

Natalie!Matosin!!

!

32!

!
The! majority! of! previous! investigations! examining! mGluR5! protein! by! immunoblot! in! postmortem!
brain!samples!from!schizophrenia!subjects!identified!no!change!in!mGluR5!protein!levels!in!the!preS
frontal!cortex!(PFC),!specifically!Brodmann’s!areas!(BA)!9,!10,!11,!32!and!46!as!well!as!the!caudate,!
putamen!and!nucleus!accumbens!(Corti!et!al.,!2011;!Gupta!et!al.,!2005;!Matosin!et!al.,!2013).!In!conS
trast!to!these!findings,!Fatemi!and!colleagues!recently!reported!a!large!reduction!in!mGluR5!(monoS
mer)!protein!levels!in!the!BA9!and!lateral!cerebellum!of!schizophrenia!subjects!(Fatemi!et!al.,!2013).!
Although! these! contradictions! may! be! due! to! cohortSspecific! differences,! these! findings! raise! the!
strong!probability!that!alterations!to!mGluR5!in!schizophrenia!are!brainSregion!specific,!highlighting!
that!regional!differences!can!occur!even!between!adjacent!brain!regions,!and!thus!it!is!important!to!
explore!all!regions!independently.!!
!
Few! groups! have! examined! mGluR5! binding! in! neuropsychiatric! disorder,! although! this! is! an! imS
portant!approach!as!it!is!useful!for!quantifying!binding!sites!of!interest.!We!were!recently!the!first!to!
measure! the! MPEP! binding! site! of! mGluR5! in! the! dorsolateral! prefrontal! cortex! (DLFPC)! of! schizoS
phrenia!subjects!(Matosin!et!al.,!2013).!Whilst!overall!we!found!no!change!in!the!DLPFC,!we!did!obS
serve!a!reduction!in!binding!in!schizoaffective!subjects!of!depressive!subtype!(unpublished!observaS
tion,!due!to!limited!sample!size!n=3S4).!In!accordance,!Deschwanden!and!colleagues!(2011)!previousS
ly!reported!region!specific!reductions!in!in6vivo!mGluR5!binding!(using![11C]!ABP688)!to!the!MPEP!
site!in!multiple!regions!of!the!PFC,!insula,!and!parts!of!the!parietal!and!temporal!cortices!in!individuS
als! with! depression.! mGluR5! binding! also! correlated! with! depressive! symptom! severity.! It! is! thereS
fore!possible!that!mGluR5!may!be!reduced!in!patients!displaying!prominent!negative!(i.e.!depressive)!
symptoms! in! schizophrenia,! although! further! experimentation! is! required! to! confirm! this! notion.!
Nonetheless,! considering! many! novel! mGluR5! drugs! target! the! MPEP! site,! our! findings! suggest! that!
this!binding!site!is!accessible!in!these!disorders,!at!least!in!the!DLPFC.!
!
Although!there!is!strong!evidence!for!a!role!of!mGluR5!in!the!pathology!of!schizophrenia,!the!exact!
nature!of!its!involvement!is!unclear.!Indirect!results!from!animal!manipulation!studies!(i.e.!mGluR5!
knockout! and! mGluR5! antagonism)! indicates! involvement! of! mGluR5,! however,! some! data! from!
postmortem!human!studies!suggest!that!mGluR5!is!not!altered!in!schizophrenia.!These!negative!findS
ings!may!be!explained!by!alteration!of!mGluR5!function,!rather!than!expression,!or!concealed!due!to!
heterogeneity!within!the!examined!cohorts.!Alternatively,!alterations!in!mGluR5!may!be!brainSregion!
specific.! No! studies! to! date! have! explored! whether! there! is! altered! regulation! of! mGluR5! in! schizoS
phrenia!in!the!postmortem!brain!or!in!animal!models,!although!this!is!critical!to!uncover,!as!alteraS
tions!to!mGluR5!may!play!a!significant!role!in!the!pathophysiology!of!schizophrenia!and!might!also!
impact!on!the!efficiency!of!mGluR5Stargeted!therapeutics.!
!
Table!1.2!Summary!of!mGluR5!investigations!in!postmortem!human!brain!samples!from!
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patients!with!schizophrenia,!major!depression!or!bipolar!disorder.!(Adapted!from!Newell!et!
al.,!2014).!
Study!

Subjects!

Brain!region!

Analysis!

Outcome!

Matosin!et!al.,!
2014!

15!SZ!
15!MD!
15!BP!
15!CT!
!
12!CT!
12!MDNP!
12!MDP!

ACC!

Receptor!autoraS
diography!
([3H]MPEP)!labelS
ling!of!mGluR5.!
!

Fatemi!et!al.,!
2013!

20!SZ!
19!BP!
29!CT!!
!

PFC!(BA9)!
!
!

qRTSPCR!of!
GRM5.!ImmunobS
lot!analysis!of!
mGluR5.!

15!SZ!
14!MD!
15!BP!
14!CT!

Lateral!cerebelS
la!

qRTSPCR!of!
GRM5.!ImmunobS
lot!analysis!of!
mGluR5.!

No!overall!change!in!
mGluR5!binding!in!
SZ,!MD,!BP,!but!difS
ferential!age!associS
ations!were!present.!
No!overall!change!in!
mGluR5!binding!in!
MDNP!or!MDP,!but!
differential!age!asS
sociations!were!preS
sent.!
Reduction!in!
mGluR5!mRNA!in!
BP!but!not!SZ!or!MD.!
Reduction!in!
mGluR5!protein!
(monomer,!but!not!
dimer)!in!SZ!and!BP.!!
Reduction!in!
mGluR5!mRNA!in!SZ!
and!MD.!Reduction!
in!mGluR5!(monoS
mer!and!dimer)!proS
tein!in!SZ!and!BP,!
and!a!reduction!in!
mGluR5!protein!
(monomer!only)!in!
MD!when!standardS
ised!to!NSE,!but!not!
ßSactin.!

Matosin!et!al.,!
2013!

37!SZ!
37!CT!

DLPFC!(BA46)!

No!change!in!
mGluR5!binding!or!
protein!(monomer)!
expression!in!SZ.!

Corti!et!al.,!
2011!

21!SZ!!
35!CT!

PFC!(BA10)!

Receptor!autoraS
diography!
([3H]MPEP)!labelS
ling!of!mGluR5.!
Immunoblot!
analysis!of!
mGluR5.!
Immunoblot!
analysis!of!
mGluR5.!

Volk!et!al.,!
2010!

28!SZ!
14!SZA!
42!CT!

PFC!(BA9)!

qRTSPCR!of!
GRM5.!!

Gupta!et!al.,!
2005!

16!SZ!
9!CT!

Immunoblot!for!
mGluR5.!

Ohnuma!et!al.,!
2000!

5!SZ!
6!CT!

PFC!
(BA9,11,32,46)!
caudate,!putaS
men,!nucleus!
accumbens!
Dentate!gyrus,!
cornu!ammonis!

mGluR5!mRNA!levS
els!were!not!altered!
overall!in!SZ.!HowS
ever,!SZA!subjects!
displayed!reduced!
mGluR5!mRNA!exS
pression!compared!
to!SZ!subjects.!
No!change!in!
mGluR5.!
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pression!in!SZ.!

In!situ!hybridisaS
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tion!of!transcripts! mGluR5!mRNA!in!SZ!
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and!parahippoS
campal!gyrus!

encoding!for!
subjects.!
GRM5.!
!
!
RichardsonS
12!SZ!
Thalamus!
In!situ!hybridisaS
No!change!in!
Burns!et!al.,!
8!CT!
tion!of!transcripts! mGluR5!mRNA!in!SZ!
2000!
encoding!for!
subjects.!
GRM5.!
!
!
Ohnuma!et!al.,! 7!SZ!
PFC!(BA!9,!10,!
In!situ!hybridisaS
mGluR5!mRNA!inS
1998!
10!CT!
11)!
tion!of!transcripts! creased!in!layer!III!
encoding!for!
of!BA!11!in!SZ.!
GRM5.!
!
!
!
!
!
Abbreviations:! BA,! Brodmann’s! Area;! BP,! bipolar! disorder;! CT,! control;! MD,! major! depression;! MDP,! major!
depression! with! psychosis;! MDNP,! major! depression! without! psychosis;! mGluR5,! metabotropic! glutamate! reS
ceptor! 5;! [3H]MPEP,! tritiated! 2SMethylS6S(phenylethynyl)pyridine;! PFC,! prefrontal! cortex;! qRTSPCR,! quantitaS
tive!real!time!polymerase!chain!reaction;!SZ,!schizophrenia;!SZA,!schizoaffective!disorder.!
!

1.1.6!! The!effects!of!current!APDs!on!mGluR5!
APDs! are! currently! the! primary! form! of! treatment! for! schizophrenia! patients.! Whilst! both! first,! seS
cond!and!third!generation!APDs!competitively!antagonise!dopamine!D2!receptors,!second!and!third!
generation!APDs!have!a!much!more!complex!mode!of!action!with!various!affinities!for!dopaminergic,!
serotonergic,!muscarinic,!adrenergic!and!histamatergic!receptors!(Coward,!1992;!Seeman,!2002).!DeS
spite! being! widely! efficacious! for! positive! schizophrenia! symptoms,! APDs! display! minimal! benefits!
for! negative! and! cognitive! symptom! profiles! for! many! patients! (HerescoSLevy,! 2003).! In! addition,!
APDs!cause!a!large!array!of!adverse!effects,!including!obesity,!metabolic!syndrome,!sedation!and!moS
tor!dysfunction!among!more!(Kane,!2011).!
!
There!are!few!studies!investigating!the!involvement!of!mGluR5!in!the!mechanisms!of!current!APDs.!
Chronic! administration! of! clozapine! in! mGluR5! knockout! mice! improved! sensorimotor! gating! and!
NMDARSantagonist! induced! hyperactivity,! although! it! did! not! improve! memory! deficits,! suggesting!
modulation!of!mGluR5!is!necessary!for!these!therapeutic!effects!(Gray!et!al.,!2009).!For!this!reason,!it!
is!important!to!understand!whether!current!medications!can!influence!the!expression!and/or!activity!
of!mGluR5,!and!also!to!allow!for!the!interpretation!of!postmortem!human!data!where!there!was!preS
mortem! exposure! to! APDs.! The! three! previous! studies! investigating! the! effects! of! APDs! on! mGluR5!
levels! (notably,! this! is! irrespective! of! modelling! disease)! are! summarised! in! Table! 1.3.! We! have! reS
cently! shown! that! acute,! subchronic! and! chronic! treatments! with! typical! (haloperidol)! and! atypical!
(olanzapine)!APDs!do!not!influence!mGluR5!binding!density!in!the!rat!PFC,!hippocampus!or!striatum!
(Matosin!et!al.,!2013).!Another!study!however!has!shown!that!mGluR5!mRNA!expression!is!increased!
by! typical! (haloperidol)! and! atypical! (sertinadole)! APD! treatment! in! the! anterior! cingulate! cortex!
(ACC)! and! striatum! in! Sprague! Dawley! rats! (Iasevoli! et! al.,! 2010).! However,! it! should! be! noted! that!
Iasevoli!and!colleagues!used!almost!double!the!dose!of!these!APDs,!and!thus!the!ability!to!compare!
these!results!is!impeded.!Additionally,!it!must!be!noted!that!mRNA!levels!do!not!denote!correspondS
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ing!changes!in!protein!expression!(Greenbaum!et!al.,!2003).!Furthermore,!previous!studies!have!not!
considered!whether!mGluR5!regulation!may!be!affected!by!APD!treatment.!
!
Table!1.3!Summary!of!mGluR5!investigations!in!animal!models!of!APD!treatment.!(Adapted!from!
Newell!et!al.,!2014)!
Study!

Animals!

Treatment!

Analysis!

Outcome!

Matosin!et!
al.,!2013!

Male!adult!SpragueS
Dawley!rat!
(n=6/group).!

Haloperidol,!
0.1mg/kg!3!
times!per!
day,!OR!
olanzapine,!
1mg/kg,!3!
times!per!
day,!p.o.!for!
8,16!or!36!
days.!SacriS
ficed!48!
hours!after!
last!treatS
ment.!
Haloperidol,!
0.8mg/kg,!
OR!
Sertindole,!
2mg/kg,!s.c.!
injection!for!
21!days,!
sacrificed!90!
mins!after!
the!last!
treatment.!!

Receptor!autoradiogS
raphy!([3H]MPEP)!
labelling!of!mGluR5.!
!

No!effect!of!
haloperidol!or!
olanzapine!
treatment!on!
mGluR5!bindS
ing.!

In!situ!hybridisation!
of!mGluR5!mRNA.!
!

Increased!
mGluR5!mRNA!
in!medial!(DM!
and!VM)!striaS
tum,!ACC!and!
motor!cortices!
in!response!to!
both!treatS
ments.!No!difS
ference!in!hipS
pocampus.!
Increased!
mGluR5!mRNA!
in!DL!striatum!
after!sertindole!
treatment!only.!
No!change!in!
mGluR5!mRNA!
expression!afS
ter!any!treatS
ment.!

Iasevoli!et!al.,! Male!adult!SpragueS
2010!
Dawley!rats!(n=7).!

Tascedda!et!
al.,!2001!

Male!SpragueSDawley!
rats!(n=6S8/group).!

Haloperidol! Probe!Preparation!
(1mg/kg),!
and!RNase!Protection!
clozapine!
Assay!!
(10mg/kg),!
or!olanzapS
ine!
(2mg/kg)!
s.c.,!daily!for!
1!(acute)!or!
21!(chronic)!
days.!SacriS
ficed!6!
hours!after!
last!treatS
ment.!
!
!
!
!
!
3
Abbreviations:! mGluR5,! metabotropic! glutamate! receptor! 5;! [ H]MPEP,! tritiated! 2SMethylS6S
(phenylethynyl)pyridine;!p.o.,!per!oral;!s.c.!subcutaneous.!

!
It!remains!unclear!whether!mGluR5!is!affected!by!current!APDs,!however,!it!has!been!suggested!that!
interactions!occur!between!mGluR5!and!D2!receptors,!a!major!target!of!most!APDs.!mGluR5!protein!
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expression!was!reported!to!be!decreased!in!the!rat!PFC!following!chronic!adolescent!treatment!with!
the!potent!dopamine!agonist,!apomorphine!(Shao!et!al.,!2010).!This!mechanism!of!action!may!be!atS
tributable!to!“receptor!mosaics”,!a!term!coined!by!the!Agnati/Fuxe!group,!whereby!receptors!may!be!
coupled!physically!resulting!in!more!complex!signalling!pathways!(Fuxe!et!al.,!2008).!This!group!reS
ported!that!D2!and!mGluR5!form!heterodimers!in!the!striatum,!particularly!at!the!corticostriatal!gluS
tamate! synapse,! raising! the! possibility! that! mGluR5! was! altered! by! apomorphine! via! this! pathway.!
This!linkage!(mGluR5SD2)!provides!an!avenue!of!interaction!between!glutamatergic!and!dopaminerS
gic!transmission.!Dysfunctions!within!these!neurochemical!systems!are!reflective!of!positive,!negative!
and! cognitive! symptomatology.! Thus,! it! is! possible! that! current! APDs! may! exert! therapeutic! effects!
indirectly!via!mGluR5,!although!this!has!not!been!experimentally!confirmed.!
!

1.1.7!! mGluR5!as!a!future!treatment!target!for!schizophrenia!
As! aforementioned,! currently! available! APDs! have! some! efficacy! for! positive! schizophrenia! sympS
toms,!but!have!minimal!benefits!for!the!negative!and!cognitive!symptoms!in!many!patients,!and!are!
often!accompanied!by!severe!side!effects!(HerescoSLevy,!2003).!Due!to!the!strong!evidence!that!gluS
tamate!is!involved!in!all!aspects!of!schizophrenia!symptomatology,!including!cognition,!many!groups!
have! aimed! to! develop! drugs! aimed! at! the! glutamatergic! system! which! are! wellStolerated! with! reS
duced!adverse!effects!(Rubio!et!al.,!2012).!However,!as!the!NMDAR!cannot!be!directly!agonised!as!a!
therapy!for!schizophrenia!due!to!the!high!risk!of!excitotoxicity,!receptor!desensitisation,!and!adverse!
side! effects,! modulation! of! glutamatergic! transmission! via! mGluR5! is! promising.! For! example,! the!
functional! and! physical! link! to! the! NMDAR! provides! a! way! to! indirectly! modulate! dysfunctional!
NMDAR! activity.! In! addition,! mGluR5! is! selectively! distributed! in! brain! regions! relevant! to! schizoS
phrenia,!reducing!the!chances!of!excitotoxicity.!mGluR5!agonists!have!been!shown!to!ameliorate!cogS
nitive! impairments! induced! by! NMDAR! antagonists! in! animals! (Lecourtier! et! al.,! 2007;! Stefani! and!
Moghaddam,!2010;!Vales!et!al.,!2010).!Additionally,!Kinney!et!al.!(2006)!reported!that!mGluR5!agoS
nism!attenuated!NMDAR!antagonist!induced!deficits!in!parvalbumin,!a!calciumSbinding!protein!which!
is!well!documented!to!be!altered!in!schizophrenia.!However,!due!to!cytotoxic!effects!associated!with!
direct! agonism,! positive! allosteric! modulators! (PAMs)! are! the! preferred! candidates! for! drug! develS
opment.!PAMs!do!not!activate!receptors!directly,!rather!they!act!on!an!allosteric!site!to!potentiate!acS
tivation!by!glutamate!(Conn!et!al.,!2009).!
!
PAMs!of!mGluR5,!the!majority!acting!at!the!MPEP!allosteric!binding!site,!reverse!a!wideSrange!of!posiS
tive,! negative! and! cognitive! schizophreniaSlike! behaviours! induced! in! both! dopaminergic! (i.e.! amS
phetamine)! and! glutamatergic! (i.e.! MKS801/PCP)! animal! models! of! schizophrenia.! mGluR5! PAMs!
have!also!been!reported!not!to!cause!sedation!(Gilmour!et!al.,!2013;!ParmentierSBatteur!et!al.,!2013),!
or!other!unwanted!behavioural!side!effects!(Balschun!et!al.,!2006),!although!“very!mild”!catalepsy!has!
been! reported! for! some! of! these! agents! at! high! doses! (Liu! et! al.,! 2008;! Schlumberger! et! al.,! 2010).!
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Considering! the! role! of! mGluR5! in! cognitive! function,! mGluR5Stargeting! drugs! may! be! particularly!
useful!for!the!treatment!of!cognitive!deficits!associated!with!the!disorder.!Nonetheless,!there!is!limS
ited! knowledge! regarding! the! status! of! mGluR5! in! the! pathological! state! (i.e.! alterations! in! protein!
levels,! binding! ability,! function,! regulation! or! signalling),! despite! that! pathological! alterations! to!
mGluR5!could!impact!on!the!therapeutic!efficacy!of!these!agents.!It!is!therefore!critical!to!understand!
the!status!of!mGluR5!in!the!pathological!state!to!guide!the!development!of!mGluR5Sbased!treatments.!
!

1.2!!

Literature!summary!

mGluR5! is! an! important! modulator! of! glutamatergic! neurotransmission,! particularly! via! its! interacS
tion! with! the! NMDAR,! which! is! widely! reported! to! be! altered! in! schizophrenia! pathology,! and! has!
therefore!come!to!light!as!a!protein!that!might!also!be!involved!in!the!pathophysiology!of!the!disorS
der.!In!support,!mGluR5!is!critically!involved!in!cognitive!function,!which!is!impaired!in!patients!with!
schizophrenia.! mGluR5! is! thus! a! compelling! therapeutic! target! for! the! treatment! of! schizophrenia,!
particularly!the!cognitive!deficits.!!
!
Accumulating! evidence! suggests! there! could! be! aberrations! of! mGluR5! translation,! expression! or!
function!in!individuals!with!schizophrenia,!including!studies!that!indicate!that!genetic!variation!withS
in! GRM5)is! associated! with! schizophrenia,! and! evidence! from! animal! studies! indicating! that! altered!
mGluR5! activity! induces! schizophreniaSlike! behaviours.! Specifically,! pharmacological! blockade! of!
mGluR5!in!animals!produces!a!range!of!schizophreniaSrelated!behaviours,!especially!deficits!in!workS
ing! memory,! instrumental! learning,! spatial! memory! and! social! interaction.! Additionally,! mGluR5!
knockout!mice!display!strong!schizophreniaSlike!behaviours,!including!reduced!sensorimotor!gating!
and!spatial!memory.!Finally,!mGluR5!upregulation!has!promising!therapeutic!potential!in!preclinical!
animal!models!of!schizophrenia.!Studies!aimed!to!confirm!alterations!to!mGluR5!protein!in!postmorS
tem!human!brain!studies!have!however!reported!conflicting!results,!most!likely!due!to!small!patient!
cohorts!and!the!polygenic!nature!of!schizophrenia.!In!addition,!studies!examining!mGluR5!have!not!
advanced!beyond!the!surface!to!examine!whether!mGluR5!regulation!is!affected.!This!is!important!to!
explore,!not!only!to!increase!the!current!understanding!of!the!underlying!molecular!biology!of!schizS
ophrenia,! but! also! to! determine! whether! mGluR5! S! as! a! potential! novel! therapeutic! target! S! will! be!
affected!in!the!patient.!!
!
Lastly,!although!preliminary!data!regarding!APD!effects!on!mGluR5!is!conflicting,!the!effects!of!comS
monly!used!pharmacotherapies!on!mGluR5!regulation!have!not!been!explored.!The!effects!of!current!
APD! medication! on! the! mGluR5! system! will! contribute! to! the! current! understanding! of! (i)! whether!
postmortem!measures!in!the!schizophrenia!brain!are!confounded!by!the!patients’!premortem!mediS
cation!history,!(ii)!how!mGluR5Stargeted!therapeutics!might!work!in!patients!already!exposed!to!curS
rent!APD!treatment,!and!(iii)!whether!mGluR5!might!be!used!as!an!adjunct!treatment!(particularly!to!
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treat!cognitive!dysfunctions)!in!patients!already!successfully!treated!with!current!APDs.!Collectively,!
uncovering! the! molecular! alterations! (particularly! protein! expression! and! function)! occurring! in!
schizophrenia,!and!how!these!molecules!are!effected!by!current!therapeutics,!will!help!to!build!a!solid!
foundation!for!the!tailoring,!development!and!employment!of!novel!treatments!for!schizophrenia.!
!
!
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1.2.1!! Aims!and!hypotheses!
1.2.1.1)General)aim)
To!investigate!whether!GRM5,)mGluR5,!and!mGluR5!regulation!is!affected!in!the!pathology!of!schizoS
phrenia,!to!better!understand!the!underlying!neurobiology!of!schizophrenia!and!the!treatment!potenS
tial!of!mGluR5!in!patients!with!schizophrenia.!
!

1.2.1.2)Specific)aims)
The!specific!aims!of!this!PhD!were:!
1. To!characterise!the!binding!density!of!mGluR5!in!the!ACC!(which!is!highly!involved!in!emotion!
and! cognition)! of! patients! with! schizophrenia,! bipolar! disorder! or! major! depression! (with! and!
without!psychosis).!This!study!was!designed!to!deconstruct!the!overlapping!nature!of!psychiatric!
disorders,! to! determine! which! changes! are! specific! to! mGluR5! and! schizophrenia.! (Presynaptic!
mGluR2/3!were!also!included!in!the!original!study!design!to!provide!additional!context.)!!
2. To!determine!whether!mGluR5!and!mGluR5!regulators!are!altered!in!postmortem!samples!from!
the!DLPFC,!which!is!a!region!associated!with!working!memory,!cognitive!flexibility,!planning,!inS
hibition,!and!abstract!reasoning,!of!subjects!with!schizophrenia.!
3. To!determine!whether!alterations!in!mGluR5!and!mGluR5!regulators!extend!to!the!hippocampal!
CA1! region! (highly! implicated! in! cognitive! processes,! including! several! types! of! learning! and!
memory!formation!and!storage)!of!subjects!with!schizophrenia.!
4. To!determine!whether!commonly!used!APD!treatments!for!schizophrenia!affect!mGluR5!expresS
sion!or!regulation!in!a!pharmacological!animal!model.!
5. To!determine!whether!novel!SNPs!within!GRM5!are!associated!with!schizophrenia,!and!whether!
genetic! variation! within! GRM5! could! contribute! to! cognitive! dysfunction! in! schizophrenia! subS
jects!using!a!caseScontrol!cohort!for!this!disorder.!!
!

1.2.1.3)Hypotheses))
1. Despite!the!preliminary!findings!in!the!DLPFC!that!mGluR5!is!not!altered!in!schizophrenia!subS
jects!but!is!reduced!in!schizoaffective!subjects!of!depressive!subtype!(Matosin!et!al.,!2013),!it!was!
hypothesised!that!mGluR!binding!density!would!be!reduced!in!the!ACC!of!patients!with!schizoS
phrenia,!major!depression!and!bipolar!disorder,!due!to!the!role!of!the!ACC!in!emotion!and!mood!
which!are!processes!disrupted!in!these!three!disorders.!However!based!on!the!previous!findings!
in!the!DLPFC,!it!was!further!hypothesised!that!mGluR5!reduction!would!be!pronounced!in!subS
jects!with!major!depression.!
2. Considering!evidence!of!NMDAR!hypofunction!in!this!same!postmortem!cohort!(Weickert!et!al.,!
2012),! the! results! from! animal! studies! that! mGluR5! knockout! or! antagonism! produces! schizoS
phreniaSlike!behaviours!(Matosin!and!Newell,!2013),!and!reports!of!the!importance!of!the!DLPFC!
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in!schizophrenia!pathology!(Callicott!et!al.,!2000),!it!was!hypothesised!that!mGluR5!protein!and!
endogenous!regulation!would!be!reduced!in!the!postmortem!DLPFC!in!schizophrenia.!
3. In!view!of!the!extensive!evidence!of!(i)!hippocampalSdependent!cognitive!impairment!in!schizoS
phrenia!(Harrison,!2004),!(ii)!the!specific!role!of!mGluR5!in!modulating!synaptic!plasticity!in!the!
CA1! region! in! schizophrenia! (Mukherjee! and! ManahanSVaughan,! 2013),! and! (iii)! evidence! that!
mGluR5!knockout!or!antagonism!induces!deficits!in!hippocampalSdependent!cognitive!functions!
in! rodents,! it! was! hypothesised! that! protein! levels! of! mGluR5! and! mGluR5! signalling! partners!
would!be!reduced!in!the!CA1!region!of!postmortem!schizophrenia!brains.!
4. mGluR5!is!highly!involved!in!cognitive!function,!and!current!APD!have!minimal!effects!on!cogniS
tive!deficits!in!many!schizophrenia!patients!(Harvey,!2013).!Accordingly,!clozapine!was!unable!to!
reverse!cognitive!deficits!in!mGluR5!knockout!mice!(Gray!et!al.,!2009),!suggesting!mGluR5!plays!
a!fundamental!role!in!mediating!cognitive!behaviours.!It!was!thus!hypothesised!that!current!APD!
treatment!in!rats!would!not!affect!protein!expression!of!mGluR5!or!mGluR5!signalling!partners!
in!the!cortex!or!hippocampus.!
5. As!(i)!Devon!et!al.!(2001)!and!Timms!et!al.!(2013)!have!both!reported!differential!disruptions!to!
GRM5!in!families!with!schizophrenia,!(ii)!an!intronic!microsatellite!within!GRM5)was!previously!
associated!with!schizophrenia!in!a!caseScontrol!population!(Devon!et!al.,!2001),!(iii)!GRM5)was!
recently! reported! to! be! a! top! candidate! in! psychiatric! pathology! (Ayalew! et! al.,! 2012),! and! (iv)!
the!hypothesis!that!mGluR5!is!dysregulated!in!schizophrenia,!it!was!hypothesised!that!the!tested!
polymorphisms!within!the!3’!UTR!of!GRM5!would!be!significantly!associated!with!schizophrenia!
in!the!studied!population.!Furthermore,!due!to!the!extensive!evidence!that!mGluR5!is!involved!in!
the!mechanisms!underlying!synaptic!plasticity,!it!was!further!hypothesised!that!allelic!variation!
within!GRM5!would!affect!cognition!in!patients!with!schizophrenia.!
!

!
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1.2.1.4)Significance))
Schizophrenia! affects! approximately! 24! million! people! worldwide,! but! current! therapeutic! treatS
ments!for!these!patients!are!inadequate!for!many!sufferers.!Understanding!the!causes!and!neurobiolS
ogy! of! schizophrenia! is! critical! to! developing! more! successful! treatments! with! minimal! side! effects.!
For!the!first!time,!the!studies!within!this!thesis!addressed!whether!mGluR5!and!mGluR5!regulation!is!
affected!in!schizophrenia!or!by!current!APD!medication,!and!whether!SNPs!within)GRM5!are!associS
ated!with!schizophrenia!and!cognition.!The!studies!presented!in!this!thesis!add!to!the!limited!literaS
ture!regarding!GRM5/mGluR5,!and!its!role!in!the!emergence!and!neurobiology!of!schizophrenia.!FurS
ther,! these! studies! provide! critical! information! regarding! the! status! of! mGluR5! in! the! pathology! of!
schizophrenia,!which!is!necessary!to!guide!the!development!of!future!therapeutics!aimed!at!mGluR5.!!

!

!
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Chapter(Two!
!

!
2.1!

Brief!introduction!

The!content!of!Chapter!Two!includes!Study!1:!Is!mGluR5!binding!density!altered!in!the!ACC!in!the!
pathophysiology!of!psychotic!and!mood!disorders?!
!

2.1.1! Relevant!aims!
This!study!was!designed!to!address!Aim!1:!!
1.!To!characterise!the!binding!density!of!mGluR5!in!the!ACC!(which!is!highly!involved!in!emotion!
and! cognition)! of! patients! with! schizophrenia,! bipolar! disorder! or! major! depression! (with! and!
without!psychosis).!This!study!was!designed!to!deconstruct!the!overlapping!nature!of!psychiatric!
disorders,! to! determine! which! changes! are! specific! to! mGluR5! and! schizophrenia.! (Presynaptic!
mGluR2/3!were!also!included!in!the!original!study!design!to!provide!additional!context,!such!as!to!
determine!if!alterations!are!specific!to!mGluR5.)!
!

2.1.2! Overview!and!general!methods!
2.1.2.1))Study)rationale)
Previous!studies!that!examined!mGluR5!in!the!postmortem!schizophrenia!brain!have!largely!reportS
ed!little!significant!difference!in!mGluR5!mRNA!or!protein!expression!in!schizophrenia!compared!to!
control! subjects,! although! this! might! be! brainSregion! dependent! (see! Chapter! 1,! section! 1.1.5.3! and!
Table!1.2).!However,!we!previously!found!preliminary!evidence!of!a!decrease!in!mGluR5!in!schizoafS
fective!subjects!of!depressive!subtype!(unpublished!observations),!suggesting!alterations!in!mGluR5!
may!be!associated!with!different!symptom!profiles!in!patients,!and!specifically,!depressiveSlike!sympS
toms.!Reductions!in!mGluR5!binding!have!also!been!previously!reported!in!the!PFC!of!subjects!with!
major!depression!(Deschwanden!et!al.,!2011).!This!study!therefore!aimed!to!analyse!whether!alteraS
tions!to!mGluR5!are!specific!to!depressive!or!psychotic!symptoms!using!two!wellSestablished!brain!
cohorts.!
!
)

)
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2.1.2.2))Methods)overview)
!
(a)!SUBJECTS,!STRUCTURE!AND!DESIGN:!
!

!
!
(b)!RECEPTOR!AUTORADIOGRAPHY!TECHNIQUE:!

!

!

Figure! 2.1! Methodological! overview! of! Study! 1.! (a)! Subjects! in! this! study! were! derived! from! two! wellS
characterised!postmortem!cohorts,!consisting!of!subjects!with!schizophrenia,!bipolar!disorder!or!major!depresS
sion!(with!or!without!psychosis).!The!anterior!cingulate!cortex!of!these!subjects!was!examined!using!the!recepS
tor!autoradiography!technique!as!seen!in!(b).!Brain!slices!were!incubated!with!a!tritiated!specific!ligand!(hot)!
for!either!mGluR5!(MPEP)!or!mGluR2/3!(LY341495),!and!non!specific!binding!(cold)!determined!by!incubation!
in! nonSlabeled! specific! ligands! for! these! receptors! (MPEP! and! DCGSIV).! Abbreviations:! DCGSIV,! (1R,2R)S3S
[(1S)S1SaminoS2ShydroxyS2Soxoethyl]cyclopropaneS1,2Sdicarboxylic! acid;! LY341495,! Eli! Lilly! and! Company!
compound!341495,!also!known!as!Eglumegad;!MPEP,!2SMethylS6S(phenylethynyl)pyridine.!

!

!
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2.1.3! Result!summary!
The!results!from!Study!1!(Chapter!2)!indicate!that!mGluR5!(and!mGluR2/3)!binding!is!not!altered!in!
the! ACC! or! in! schizophrenia,! bipolar! disorder! or! major! depression! with! or! without! psychosis,! comS
pared!to!control!subjects.!Although!these!results!suggest!that!novel!therapeutics!that!target!mGluR5!
will!be!unhindered,!at!least!in!this!brain!region,!alterations!to!receptor!regulation!or!function!cannot!
be! discounted.! In! addition,! the! finding! of! differential! ageSrelated! differences! in! mGluR2/3! binding!
across! the! studied! disorders! suggest! there! may! be! differential! treatment! responses! to! these! novel!
therapeutics!depending!on!the!pathology!and!age!of!the!patient.!!
!

2.1.4! Author!contributions!!
N.! Matosin! performed! the! experiments,! acquired! and! analysed! the! data,! wrote! the! first! draft! of! the!
manuscript,!which!all!authors!reviewed!and!approved!for!publication.!
!

2.1.5! Collaborator’s!statements!
!
We! hereby! declare! that! the! statement! in! section! 2.1.4! pertaining! to! the! contributions! of! N.! Matosin!
are!correct.!
!
!
Francesca!FernandezSEnright! !
!
!
Elisabeth!Frank!
!
!
!
!
Chao!Deng!
!
!
!
!
!
Jenny!Wong! !
!
!
!
!
XuSFeng!Huang!!
!
!
!
!
Kelly!Newell! !
!
!

!

!

Natalie!Matosin!!

!

45!

1
2

!

Reprinted!from!Journal)of)Psychiatry)&)Neuroscience!2014;39(6):407S16!!http://jpn.ca/vol39Sissue6/39S6S407/!!
!

2.1.6! Manuscript! one:! Metabotropic! glutamate! receptor! mGluR2/3! and! mGluR5!
binding! in! the! anterior! cingulate! cortex! in! psychotic! and! nonpsychotic! depression,!
bipolar!disorder!and!schizophrenia:!implications!for!novel!mGluR0based!therapeutics!
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Chapter(Three!
!

!
3.1!

Brief!introduction!

The!content!of!Chapter!Three!includes!Study!2:!Is!mGluR5!or!mGluR5!regulation!affected!in!the!
DLPFC!of!schizophrenia!subjects,!or!by!APD!treatment?!
!

3.1.1! Relevant!aims!
This!study!was!designed!to!address!Aims!2!and!4:!!
2.!To!determine!whether!mGluR5!and!mGluR5!regulators!are!altered!in!postmortem!samples!from!
the!DLPFC,!which!is!a!region!associated!with!working!memory,!cognitive!flexibility,!planning,!inhiS
bition,!and!abstract!reasoning,!of!subjects!with!schizophrenia.!
4.!To!determine!whether!commonly!used!APD!treatments!for!schizophrenia!affect!mGluR5!or!
mGluR5!endogenous!regulators!in!the!PFC!of!a!pharmacological!animal!model.!
!

3.1.2! Overview!and!general!methods!
3.1.2.1)Study)rationale)
Although!the!levels!of!cortical!mGluR5!protein!and!mRNA!are!largely!reported!to!be!unaltered!in!
schizophrenia,!the!regulation!of!mGluR5!in!schizophrenia,!or!response!of!mGluR5!to!commonly!used!
therapeutics,!has!never!before!been!considered.!Studies!solely!examining!mGluR5!are!not!sufficient!to!
conclude!that!mGluR5!is!unaffected!in!schizophrenia.!Therefore,!this!study!was!designed!to!assess!
whether!mGluR5,!as!well!as!important!novel!mGluR5!endogenous!regulators!(Norbin,!Preso1!and!
Tamalin)!were!altered!in!the!postmortem!schizophrenia!brain!or!affected!by!current!and!commonly!
prescribed!APDs.!
!
)
)
)
)
)
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3.1.2.2)Methods)overview)
!
(a)!SUBJECTS,!STRUCTURES!AND!DESIGN:!!
Human:)
!
!
!
!
!
!
!
Animal:!!
!

!

!
!
!
!
(b)!IMMUNOBLOT!PROTEIN!DETECTION!TECHNIQUE:!!
!
!
!
!
!
!

!

!
Figure!3.1!Methodological!overview!of!Study!3.!!(a)!A!large!cohort!of!37!schizophrenia!subjects!compared!to!37!
matched!controls!were!used!for!this!study.!The!DLPFC!was!examined.!Subsequently,!54!adult!male!rats!were!
divided!into!six!groups!of!3!treatments!(haloperidol,!olanzapine!and!vehicle/control)!and!3!treatmentS
durations!(8,!15!and!35!days).!The!PFC!area!of!the!rat!brain!was!analysed.!(b)!mGluR5,!Norbin,!Tamalin!and!
Preso1!were!analysed!by!immunoblot!analysis;!these!tissues!are!derived!from!the!same!animals!as!previously!
published!in!Matosin!et!al.,!2013!(Schizophrenia)Research)!Abbreviations:!DLPFC,!dorsolateral!prefrontal!corS
tex;!ST,!short!term;!MT,!medium!term;!LT,!long!term;!PFC,!prefrontal!cortex;!TRC,!tissue!resource!centre;!SDS!
polyacrylamide,!sodium!dodecyl!sulphateSpolyacrylamide.!
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3.1.3! Results!summary!
Using!a!large!postmortem!cohort,!the!results!from!Study!2!showed!that!mGluR5!protein!is!increased!
and!its!regulatory!proteins!are!decreased!in!the!DLPFC!region!of!schizophrenia!patients.!In!addition,!
Study!4!showed!that!current!commonly!used!APDs!do!not!influence!the!levels!of!mGluR5!and!its!reguS
latory!proteins.!Due!to!the!prominent!role!of!cortical!mGluR5!in!the!emergence!of!learning!and!
memory!deficits,!dysregulation!of!mGluR5!in!this!region!might!contribute!to!the!cognitive!dysfuncS
tions!that!are!observed!in!schizophrenia!patients.!Further,!as!mGluR5!and!mGluR5!modulators!are!
not!influenced!by!current!APDs,!this!provides!support!for!the!use!of!mGluR5Stargeting!drugs!for!the!
treatment!of!the!observed!alterations.!This!study!provides!strong!support!of!mGluR5!dysregulation!in!
schizophrenia,!at!least!in!the!DLPFC.!
!

3.1.4! Author!contributions!!
N.!Matosin!was!a!designer!of!this!study,!performed!the!experiments,!acquired!protein!measures,!anaS
lysed!all!the!data,!and!wrote!the!first!draft!of!the!manuscript,!which!all!authors!reviewed!and!apS
proved!for!publication.!mGluR5!mRNA!data!was!contributed!by!S.!Fung!and!C.!S.!Weickert.!AntipsyS
chotic!drug!treated!rat!brain!tissue!was!provided!by!X.F.!Huang,!which!N.!Matosin!analysed.!
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3.1.6! Manuscript!two:!Alterations!of!mGluR5!and!its!endogenous!regulators!Norbin,!

Tamalin!and!Preso1!in!schizophrenia:!towards!a!model!of!mGluR5!dysregulation!
!

Full article on page 59-69 removed for copyright reasons, please refer to the following citation:
Matosin, N., Fernandez-Enright, F., Fung, S. Jane., Lum, J. Stephen., Engel, M., Andrews, J. Lee.,
Huang, X., Weickert, C. S. & Newell, K. Anne. (2015). Alterations of mGluR5 and its endogenous
regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5
dysregulation. Acta Neuropathologica, 130 (1), 119-129.
doi: 10.1007/s00401-015-1411-6
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Chapter(Four!
!

!
4.1!

Brief!introduction!

The!content!of!Chapter!Four!includes!Study!3:!Is!mGluR5!or!mGluR5!regulation!affected!in!the!CA1!
region!of!schizophrenia!subjects,!or!by!APD!drug!treatment?!
!

4.1.1! Relevant!aims!
These!studies!were!designed!to!address!Aims!3!and!4:!!
3.!To!determine!whether!alterations!in!mGluR5!and!mGluR5!regulators!extend!to!the!hippocampal!
CA1! region! (highly! implicated! in! cognitive! processes,! including! several! types! of! learning! and!
memory!formation!and!storage)!of!subjects!with!schizophrenia.!
4.! To! determine! whether! commonly! used! APD! treatments! for! schizophrenia! affect! mGluR5! or!
mGluR5!endogenous!regulators!in!the!PFC!of!a!pharmacological!animal!model.!
!

4.1.2! Overview!and!general!methods!
4.1.2.1)Study)rationale)
Extensive!evidence!indicates!that!mGluR5!activity!in!CA1!is!critically!involved!in!LTP/LTD,!the!mechS
anisms!underlying!proper!synaptic!plasticity!and!thus!cognitive!function.!In!accordance,!mGluR5!sigS
nalling!has!been!reported!to!modulate!working!memory,!instrumental!learning,!spatial!memory!and!
proper! sensorimotor! gating! in! rodents,! which! are! processes! also! disrupted! in! patients! with! schizoS
phrenia.!However,!the!status!of!mGluR5!in!the!hippocampus!is!largely!unknown.!This!study!therefore!
aimed!to!determine!whether!mGluR5!is!altered!in!the!hippocampal!CA1!region!in!schizophrenia!subS
jects.!
!

!
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4.1.2.2)Methods)overview)
(a)!SUBJECTS,!STRUCTURES!AND!DESIGN:!
Human:!
!
!
!
!
!
!
!
!
!
!
Animal:!!
!
!
!
!
!
!
!
!
!
!
(b)!
IMMUNOBLOT!
DETECTION!
TECH0
!
!
!
!
!
!
!
!
!
!
!
!

PROTEIN!
NIQUE:!!

!
Figure! 4.1! MethodologiS
cal! overS
view!of!Study!4.!(a)!20!schizophrenia!subjects!were!compared!to!20!matched!controls!in!this!study.!The!examS
ined!hippocampal!CA1!region!was!obtained!from!the!level!of!the!lateral!geniculate!nucleus,!and!visually!verified!
by! researchers! at! the! NSW! Tissue! Resource! Centre.! Subsequently,! 54! adult! male! rats! were! divided! into! six!
groups!of!3!treatments!(haloperidol,!olanzapine!and!vehicle/control)!and!3!treatmentSdurations!(8,!15!and!35!
days).!The!hippocampus!area!of!the!rat!brain!was!analysed;!these!tissues!are!derived!from!the!same!study!deS
scribed!in!Chapter!3!and!Matosin!et!al.,!2013!(Schizophrenia)Research).!(b)!mGluR5,!Norbin,!Tamalin!and!Preso1!
were! analysed! by! immunoblot! analysis.! Abbreviations:! CA1,! cornu! ammonis! 1;! Hip,! hippocampus;! ST,! short!
term;!MT,!medium!term;!LT,!long!term;!TRC,!Tissue!Resource!Centre;!SDS!polyacrylamide,!sodium!dodecyl!sulS
phateSpolyacrylamide.!
!
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4.1.3! Results!Summary!
For!the!first!time,!the!study!from!Chapter!4!examined!whether!mGluR5!protein!levels!are!affected!in!
the!CA1!hippocampal!region!in!postmortem!samples!from!schizophrenia!subjects.!Although!a!signifiS
cant!increase!in!mGluR5!was!detected!in!CA1,!the!results!from!this!study!were!surprising!considering!
a!decrease/abolition!of!mGluR5!induces!cognitiveSlike!deficits!in!rodent!models.!Thus,!it!is!hypotheS
sised!that!this!increase!in!mGluR5!does!not!represent!a!functional!increase,!but!rather!a!core!deficit!is!
present!affecting!mGluR5!activity!in!CA1,!resulting!in!increased!levels!of!mGluR5!and!mGluR5!endogS
enous!regulators!to!compensate!for!this!signalling!deficit.!Further,!considering!mGluR5!protein!levels!
are! increased! in! both! the! CA1! and! DLPFC! regions,! whilst! mGluR5! endogenous! regulators! are! inS
creased!in!CA1!but!deceased!in!DLPFC,!this!suggests!mGluR5!may!be!regulated!in!a!brainSregion!deS
pendent!manner.!
!

4.1.4! Author!contributions!!
N.!Matosin!was!a!designer!of!this!study,!performed!the!experiments,!acquired!protein!measures,!anaS
lysed! all! the! data,! and! wrote! the! first! draft! of! the! manuscript,! which! all! authors! reviewed! and! apS
proved!for!publication.!Antipsychotic!drug!treated!rat!brain!tissue!was!provided!by!X.F.!Huang,!which!
N.!Matosin!analysed.!
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A!newer!version!with!a!subset!of!the!data!in!this!original!transcript!is!now!accepted!at!Schizophrenia)Research,!2015:!
Matosin!N,!FernandezSEnright!F,!Lum!JS,!Andrews!JL,!Engel!M,!Huang!XF,!Newell!KA.!Metabotropic!glutamate!receptor!
5!and!its!trafficking!molecules,!Norbin!and!Tamalin,!are!increased!in!the!CA1!hippocampal!region!of!subjects!with!
schizophrenia.!(see!Appendix)!

4.1.6!

Manuscript!three:!mGluR5!and!mGluR5!endogenous!regulators!are!

increased!in!the!CA1!hippocampal!region!of!subjects!with!schizophrenia!
!

Natalie!Matosin!!

!

73!

!

Natalie!Matosin!!

!

74!

!

Natalie!Matosin!!

!

75!

!

Natalie!Matosin!!

!

76!

!
!

!

Natalie!Matosin!!

!

77!

!
!

Natalie!Matosin!!

!

78!

!
!

Natalie!Matosin!!

!

79!

!
!

Natalie!Matosin!!

!

80!

!
!

Natalie!Matosin!!

!

81!

!
!

Natalie!Matosin!!

!

82!

!
!

Natalie!Matosin!!

!

83!

!
!

Natalie!Matosin!!

!

84!

!
!

Natalie!Matosin!!

!

85!

!
!

Natalie!Matosin!!

!

86!

!
!

Natalie!Matosin!!

!

87!

!
!

Natalie!Matosin!!

!

88!

!
!

Natalie!Matosin!!

!

89!

!

!
Natalie!Matosin!!

!

90!

!

!
!

!

Natalie!Matosin!!

!

91!

!

Chapter(Five!
!

!
5.1!

Brief!introduction!

The!content!of!Chapter!Five!includes!Study!4:!Are!SNPs!within!the!regulatory!3’!untranslated!region!
of! GRM5! significantly! associated! with! schizophrenia! diagnosis,! and! associated! with! or! predictive! of!
cognitive!function!in!these!patients?!
!

5.1.1! Relevant!aims!
This!study!was!designed!to!address!Aim!5:!
5.!To!determine!whether!novel!SNPs!within!GRM5!are!associated!with!schizophrenia,!and!whether!
genetic!variation!within!GRM5!could!contribute!to!cognitive!dysfunction!in!schizophrenia!subjects!
using!a!caseScontrol!cohort!for!this!disorder.!!
!

5.1.2! Overview!and!general!methods!
5.1.2.1)Study)rationale)
Despite!that!GRM5!was!recently!identified!as!one!of!the!top!candidate!genes!for!schizophrenia!aetiolS
ogy!(Ayalew!et!al.,!2012),!and!growing!evidence!from!animal!models!for!a!role!of!GRM5)in!cognition,!
no!studies!have!investigated!the!potential!association!between!SNPs!within!GRM5!and!cognitive!feaS
tures! of! schizophrenia.! As! our! recent! postmortem! studies! suggested! dysregulation! of! mGluR5,! we!
aimed!to!investigate!whether!dysregulation!might!originate!with!genetic!variation!within!GRM5.)This!
study!thus!attempted!to!investigate!possible!associations!between!three!SNPs!located!within!the!regS
ulatory!3’!untranslated!region!(a!nonScoding!region!highly!involved!in!protein!conformation!and!regS
ulation!of!sites!responsible!for!proteinSprotein!interactions)!of!GRM5,)with!schizophrenia!and!cogniS
tive!features!in!a!Caucasian!caseScontrol!cohort.!

!
!

)
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5.2.2.2)Methods)overview)
(a)!Representation!of!GRM5!and!positions!of!chosen!SNPs!

!

!

(b)!Patient!population:!
!!
!
!
!
!
!
!
!
!
!
!
!
(d)!Statistical!methods:!

!

!

!

!!!!!!!(c)!Cognitive!measures:!

series%1%

• Are%the%allelic/genotypic%frequencies%of%the%measured%SNPs,%
within%GRM5,%signiﬁcantly%associated%with%schizophrenia%
diagnosis?%%
• ChiBsquare%analyses.%

series%2%

• Are%the%measured%SNPs%predicEve%of%cogniEve%funcEon%in%
schizophrenia%subjects?%%
• LogisEc%regression%analyses.%

series%3%

• Is%there%an%eﬀect%of%the%(SNP%x%diagnosEc%group)%interacEon,%
on%the%various%cogniEve%performance%indicators?%
• MANOVA%analyses,%with%ANOVA%and%Tukey’s%postBhoc%tesEng%
for%further%invesEgaEon%of%signiﬁcant%diﬀerences.%

!
Figure! 5.1! Methodological!overview!of!Study!5.!Abbreviations:! 3’!UTR,!3’!untranslated!region;!ANOVA,!analS
yses!of!variance;!CD,!schizophrenia!patients!characterised!by!severe!cognitive!deficits;!COWAT,!Controlled!Oral!
Word!Association!Test;!CS,!schizophrenia!subjects!characterised!as!cognitively!spared!relative!to!CD;!F,!female;!
LNS,!Letter!Number!Sequencing;!M,!male;!MANOVA,!multiple!analyses!of!variance;!RBANS,!Repeatable!Battery!
for! the! Assessment! of! Neuropsychological! Status;! SNP,! single! nucleotide! polymorphism;! WASI,! Wechsler! AbS
breviated! Scale! for! Intelligence;! WTAR,! Wechsler! Test! of! Adult! Reading;! rs,! reference! single! nucleotide! polyS
morphism;!SNP,!single!nucleotide!polymorphism.!
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5.1.3! Result!summary!
In!Chapter!5,!it!is!reported!that!(i)!rs60954128!minor!allele!(T)!and!homozygous!genotype!(TT)!were!
significantly!associated!with!schizophrenia!in!males;!(ii)!rs3824927!genotypes!significantly!predicted!
membership! of! a! subtype! of! schizophrenia! cases! characterised! by! severe! cognitive! deficits! in! male!
cases;! and,! (iii)! both! rs60954128! and! rs3824927! exerted! differential! effects! on! particular! cognitive!
domains! in! men! and! women.! These! findings! are! in! line! with! current! evidence! indicating! a! role! for!
mGluR5!in!schizophrenia!and!cognition.!The!findings!from!this!study!suggest!there!is!a!complex!assoS
ciation! between! genetic! variation! within! the) GRM5! gene! and! cognitive! function! in! schizophrenia.!
However,!the!effects!of!GRM5!polymorphisms!on!cognition!may!be!sexSspecific,!differentially!affecting!
cognitive!performance!in!men!and!women!with!and!without!schizophrenia.!

!
5.1.4! Author!contributions!
N.!Matosin!was!a!designer!of!this!study,!prepared!samples!for!analyses,!analysed!the!data,!and!wrote!
the!first!draft!of!the!manuscript,!which!all!authors!reviewed!and!approved!for!publication.!MassARS
RAY! genotyping! was! performed! by! researchers! at! the! Garvan! Institute,! Sydney.! Cognitive! data! and!
relevant!analyses!were!contributed!by!M.!Green.!

!
5.1.5! Collaborator’s!statements!
!
We! hereby! declare! that! the! statement! in! section! 5.1.4! pertaining! to! the! contributions! of! N.! Matosin!
are!correct.!
!
!
Melissa!Green! !
!
!
Kelly!Newell! !
!
!
Jessica!Andrews!

!

!

!

!

!

!

!
!
Francesca!FernandezSEnright! !
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5.1.6 Manuscript!four:!Sex!specific!associations!of!novel!gene!variants!in!
metabotropic!glutamate!receptor!5!with!schizophrenia!and!cognitive!
dysfunction!
!
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Chapter(Six!
!

!
6.1!

!Overall!discussion!and!conclusion!

The!series!of!studies!presented!in!this!thesis!collectively!support!that!mGluR5!is!dysregulated!in!the!
pathophysiology!of!schizophrenia.!The!main!findings!from!these!studies!are:!!
!
(i)

Binding! to! mGluR5! (and! related! presynaptic! receptors,! mGluR2/3)! is! not! altered! in! the!
ACC! of! schizophrenia! subjects! or! subjects! with! depression! (with! or! without! psychosis),!
bipolar!disorder!compared!to!controls!(Chapter!2;!Matosin!et!al.,!2014).!

(ii)

In!the!DLPFC,!mGluR5!mRNA!is!unaltered,!whilst!protein!levels!of!mGluR5!are!increased,!
and!mGluR5!endogenous!regulators!(Norbin,!Tamalin!and!Preso1)!are!decreased!in!schizS
ophrenia! subjects! compared! to! controls.! Also! in! this! region,! mGluR5! protein! levels! are!
significantly! correlated! with! mGluR5! mRNA,! and! protein! levels! of! mGluR5! endogenous!
regulators,!in!control!subjects!but!not!schizophrenia!subjects;!this!indicates!dysregulation!
of!mGluR5!in!schizophrenia!(Chapter!3;!Matosin!et!al.!2015,!Acta)Neuropathologica).!

(iii)

mGluR5! is! increased! in! the! hippocampal! CA1! region! in! individuals! with! schizophrenia.!
However,!as!mGluR5!knockout!induces!cognitive!deficits!in!animal!models,!it!is!hypotheS
sised! that! this! increase! (in! CA1! and! also! the! DLPFC)! does! not! represent! a! functional! inS
crease,! but! rather! a! compensatory! increase! for! a! core! deficit! in! mGluR5.! Furthermore,!
considering!mGluR5!endogenous!regulators!are!increased!in!CA1,!compared!to!the!DLPFC!
where!they!are!significantly!decreased,!this!suggests!mGluR5!may!be!regulated!in!a!brainS
region! specific! manner! (Chapter! 4;! Matosin! et! al,! accepted! Schizophrenia) Research) [see!
Appendix]).!!

(iv)

Evidence!from!the!animal!studies!in!Chapters!3!and!4!(and!the!majority!of!evidence!from!
our! human! studies)! suggest! commonly! used! APDs! do! not! influence! the! mGluR5! system!
(Matosin!et!al.,!2013,!Chapter!3!and!Chapter!4),!further!suggesting!that!our!postmortem!
findings!are!not!confounded!by!premortem!APD!history.!Additionally,!these!findings!proS
vide! evidence! that! novel! drugs! that! aim! to! correct! potential! changes! in! mGluR5! (levels,!
signalling!or!regulation)!might!be!useful!as!an!adjunct!treatment!with!current!APDs,!as!it!
is!unlikely!current!APDs!target!the!observed!alterations!in!mGluR5.!

(v)

Lastly,!SNPs!located!within!the!regulatory!3’!UTR!region!(a!key!region!involved!in!protein!
conformation!and!regulation!of!proteinSprotein!interactions)!of!GRM5,!were!significantly!
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associated!with!schizophrenia!in!men,!and!had!genderSspecific!effects!on!several!cognitive!
tests! in! both! men! and! women,! in! an! Australian! Caucasian! caseScontrol! population.! This!
suggests!that!GRM5/mGluR5!may!operate!in!a!sexSspecific!manner!(Chapter!5;!Matosin!et!
al,!submitted!American)Journal)of)Psychiatry).!!
!
Detailed!discussions!for!each!study!are!included!within!Chapters!2S5.!The!remainder!of!Chapter!6!will!
provide!a!general!discussion!of!the!main!findings!of!this!thesis.!I!will!further!discuss!necessary!conS
siderations,! the! limitations! of! these! past! and! present! works,! and! recommended! avenues! for! future!
investigations.!!
!

6.1.1! !mGluR5!in!schizophrenia:!a!summary!of!what!we!knew!
As!discussed!in!Chapter!1,!converging!lines!of!evidence!from!genetic!and!animal!studies!over!the!last!
two!decades!have!consistently!indicated!the!involvement!of!mGluR5!in!the!pathology!of!schizophreS
nia.!GRM5!knockout!or!pharmacological!blockade!of!mGluR5!induces!a!wide!range!of!schizophreniaS
like!behaviours,!including!social!interaction!deficits,!impaired!working!memory,!reduced!instrumenS
tal! learning! and! potentiation! of! deficits! induced! by! NMDAR! antagonists.! An! additional! body! of! eviS
dence! suggests! the! involvement! of! mGluR5! in! LTD! and! LTP,! which! are! the! mechanisms! underlying!
learning! and! memory! processes.! Of! these! studies,! it! is! interesting! to! note! that! differences! in! spatial!
learning! of! mice! significantly! correlated! with! protein! levels! of! mGluR5,! suggesting! mGluR5! protein!
expression! may! be! a! marker! of! deficits! in! synaptic! plasticity! and! therefore! cognitive! processes!
(ManahanSVaughan!and!Braunewell,!2005).!
!
Despite!the!results!from!animal!studies!supporting!an!important!role!of!mGluR5!in!the!manifestation!
of! schizophreniaSlike! behaviours,! the! evidence! from! human! studies! has! been! largely! inconsistent!
with! these! findings.! Postmortem! studies! inarguably! impart! an! important! understanding! of! the! moS
lecular!processes!that!underpin!neuropsychiatric!disorders.!However,!these!investigations!are!comS
monly!inconsistent!with!animal!and!cellularSbased!mechanistic!studies,!highlighting!the!complexity!of!
the!processes!involved.!Several!groups!have!previously!examined!mGluR5!measures!of!expression!in!
postmortem!samples!from!brain!regions!that!are!highly!involved!in!learning,!memory,!executive!proS
cessing!and!emotion,!including!multiple!regions!of!the!prefrontal!cortex,!hippocampus,!cingulate!corS
tices!and!deeper!structures!including!the!thalamus,!caudate!and!putamen.!However,!the!vast!majority!
of!evidence!from!these!prior!investigations!(summarised!in!Chapter!1)!have!largely!shown!mGluR5!
binding,!mRNA!and!protein!levels!are!unaltered!in!various!regions!of!the!schizophrenia!postmortem!
brain.!!
!
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It! is! however! important! to! consider! that! there! are! significant! limitations! of! many! of! these! earlier!
studies.!These!include!the!use!of!cohorts!with!limited!power!(n<20/group;!Gupta!et!al.,!2005;!Matosin!
et!al.,!2014;!Ohnuma!et!al.,!1998;!Ohnuma!et!al.,!2000b;!RichardsonSBurns!et!al.,!2000),!samples!from!
elderly!subjects!(Gupta!et!al.,!2005),!and!differences!in!experimental!techniques!used,!which!cannot!
be! compared! across! studies! (for! example,! receptor! autoradiography! compared! with! immunoblot! in!
total!homogenates,!as!previously!demonstrated:!Matosin!et!al.,!2013).!Additionally,!there!is!also!the!
possibility!of!cohortSdependent!differences,!which!can!only!be!overcome!by!repetitive!experimentaS
tion! within! independent! cohorts! of! significant! power.! These! limitations,! coupled! with! the! findings!
from! animal! studies! that! mGluR5! is! involved! in! the! manifestation! of! schizophreniaSrelated! behavS
iours,!strongly!suggested!the!need!to!further!investigate!mGluR5!in!schizophrenia!before!strong!conS
clusions!can!be!drawn.!
!
More! recently,! one! study! for! the! first! time! investigated! both! mGluR5! mRNA! and! protein! measures!
within!the!same!tissue!samples,!which!has!provided!additional!information!regarding!the!regulation!
of! mGluR5! in! schizophrenia.! Fatemi! and! colleagues! last! year! reported! that! although! there! was! no!
change! in! mGluR5! mRNA! levels! in! BA9,! there! was! decreased! levels! of! mGluR5! (monomer)! coupled!
with!both!decreased!(pan)mRNA,!as!well!as!reduced!protein!levels!of!mGluR5!(monomer)!in!the!latS
eral!cerebellum!!in!individuals!with!schizophrenia!(Fatemi!et!al.,!2013).!This!investigation!highlighted!
two! important! points.! Firstly,! mGluR5! is! likely! altered! in! a! brain! regionSspecific! manner.! Secondly,!
due!to!the!lack!of!change!in!mGluR5!mRNA!expression!but!alteration!of!mGluR5!protein!levels!in!BA9,!
this! suggests! that! the! rate! of! mGluR5! protein! synthesis! or! degradation! might! be! affected! in! this! reS
gion.!This!potential!dysregulation!has!not!been!detected!in!previous!studies!due!to!measurements!of!
only!mRNA!or!protein!levels!independently.!However,!Fatemi!and!colleagues!(2013)!did!not!present!
specific! correlations! between! mGluR5! mRNA! and! protein! levels! in! schizophrenia! and! control! paS
tients,!despite!that!this!would!be!further!indicative!of!mGluR5!synthesis!and!stability!in!this!region.!!
!
In! addition! to! the! possibility! of! altered! synthesis! and! stability! of! mGluR5,! there! are! additional! proS
cesses! that! endogenously! occur! to! regulate! mGluR5! that! may! subsequently! affect! mGluR5! function.!
Amongst!the!known!modulatory!molecules,!there!are!wellSreported!roles!for!Homer,!PSDS95,!GKAP,!
Shank,! calmodulin! and! others! (Table! 1.1;! Enz,! 2007).! These! molecules! modulate! mGluR5! signalling!
and!localisation,!and!are!reportedly!affected!in!schizophrenia!(Broadbelt!and!Jones,!2008;!Ting!et!al.,!
2012).!Some!other!compelling!examples!include!Norbin,!Tamalin!and!Preso1!(discussed!in!Chapters!
1,!3!and!4).!Despite!that!alterations!in!these!molecules!could!impair!mGluR5!activity!and!regulation!
(and!thus!contribute!to!the!pathophysiology!of!schizophrenia)!Norbin,!Tamalin!and!Preso1!have!not!
been!previously!examined!in!any!region!of!the!postmortem!schizophrenia!brain.!!!
!
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A!very!recent!study!demonstrated!that!genetic!variation!within!the!GRM5!gene!can!effect!these!proS
teinSprotein!interactions!(Timms!et!al.,!2013).!A!frameshift!within!GRM5!in!one!schizophrenia!pediS
gree!was!demonstrated!to!delete!the!Tamalin!binding!site!on!the!CSterminus!of!mGluR5,!disrupting!
Tamalin!binding!and!increasing!endocytosis!of!mGluR5.!Further,!a!missense!translating!to!the!Venus!
flytrap!domain!of!mGluR5!was!hypothesised!to!alter!glutamate!sensitivity!to!mGluR5.!Only!one!study!
previously!investigated!whether!markers!within!mGluR5!are!associated!with!schizophrenia!diagnoS
sis.!Devon!and!colleagues!microsatelliteStyped!a!Scottish!caseScontrol!population,!and!reported!the!
novel!microsatellite!was!significantly!associated!with!schizophrenia!cases!(Devon!et!al.,!2001).!More!
recently!mGluR5!has!been!named!as!one!of!the!top!candidate!genes!in!schizophrenia!aetiology,!altS
hough!SNPs!within!GRM5!have!never!before!been!investigated!for!their!association!with!the!disorder.!
It!is!possible!that!dysregulation!of!mGluR5!protein!might!originate!within!GRM5,!but!this!is!yet!to!be!
explored.!
!
There!are!therefore!several!avenues!by!which!alterations!of!mGluR5!signalling/functioning!may!ocS
cur,!which!are!beyond!the!direct!approaches!that!have!been!implemented!in!the!past.!Although!postS
mortem! studies! are! disadvantaged! as! manipulation! of! the! studied! systems! is! not! feasible,! it! is! still!
possible!to!study!some!aspects!of!protein!regulation!using!postmortem!tissue.!By!measuring!mRNA!
and!protein!levels,!as!well!as!the!levels!of!regulatory!proteins,!alterations!and!correlational!analyses!
between!measures!in!schizophrenia!subjects!compared!to!controls!provide!substantial!information.!
Thus!following!the!completion!of!Chapter!2!of!this!thesis,!where!no!change!in!mGluR5!binding!was!
again! detected! in! the! postmortem! schizophrenia! brain,! I! set! out! to! advance! the! current! knowledge!
regarding!the!status!of!mGluR5!in!schizophrenia!pathology!by!exploring!whether!mGluR5!is!dysreguS
lated!in!the!disorder.!
!

6.1.2! !mGluR5!dysregulation!in!schizophrenia:!what!we!know!now!
In!Chapter!2!of!this!thesis!(Matosin!et!al.,!2014),!mGluR5!binding!was!for!the!first!time!investigated!in!
the!ACC!of!individuals!with!schizophrenia!compared!to!controls,!but!was!not!significantly!different!in!
the! disorder.! As! mGluR5! levels! had! not! been! assessed! before! in! the! ACC,! there! are! no! studies! with!
which!these!results!can!be!compared,!although!the!results!from!this!study!were!consistent!with!my!
previous!work,!where!no!change!in!mGluR5!binding!was!reported!in!the!closely!related!DLPFC!region!
of!a!large!cohort!of!schizophrenia!patients!(Matosin!et!al.,!2013).!In!the!2013!study,!a!significant!reS
duction!of!mGluR5!was!observed!in!schizoaffective!subjects!of!depressive!subtype;!this!observation!
was!not!published!due!to!insufficient!power!(n=4),!although!the!finding!was!interesting!considering!
Deschwanden!and!colleagues!(2011)!previously!reported!reductions!of!in!vivo!binding!to!the!MPEP!
site!of!mGluR5!in!several!PFC!areas!in!individuals!with!depression,!and!binding!levels!correlated!with!
depressive!symptom!severity.!
Natalie!Matosin!!

!

!

116!

!
!
Considering!these!results,!it!was!necessary!to!further!and!extensively!investigate!whether!alterations!
of!mGluR5!were!specific!to!depressive/negative!symptoms,!both!within!schizophrenia!but!also!relatS
ed! disorders! such! as! major! depression! and! bipolar! disorder,! in! which! psychosis! and! depressive!
symptoms! overlap! (McCullumsmith! et! al.,! 2014).! The! Stanley! cohorts! (Neuropathology! Consortium!
and!Depression!Collection)!were!chosen!for!this!purpose,!as!it!allowed!some!degree!of!dissection!of!
the! overlapping! symptoms! across! schizophrenia! and! related! disorders.! The! results! indicated! that!
there! was! no! alteration! in! mGluR5! binding! or! presynaptic! mGluR2/3! binding! (which! was! added! to!
the! original! study! design! to! provide! additional! context)! specific! to! schizophrenia,! depression! (psyS
chotic!or!nonSpsychotic),!or!bipolar!disorder.!As!binding!was!not!significantly!different!in!these!neuS
ropathological! states! compared! to! controls,! these! results! also! suggest! that! mGluR5! and! mGluR2/3!
binding! sites! are! unaltered! and! therapeutics! aimed! at! these! receptors! will! be! unhindered! in! the!
pathological!states!of!schizophrenia!and!the!related!neuropsychiatric!disorders!studied.!!
!
Despite!the!fact!that!my!binding!studies!provide!a!valuable!understanding!of!the!therapeutic!utility!of!
mGluR5!and!mGluR2/3,!this!method!is!inadequate!to!assess!wider!dysregulations!of!these!receptors!
that! may! occur! within! these! pathologies,! especially! considering! the! accumulating! evidence! that!
emerged!during!the!time!of!these!studies.!This!included!studies!from:!(i)!Fatemi!and!colleagues,!indiS
cating! brainSregion! specific! dysregulation! of! mGluR5! mRNA! and! protein! levels! in! schizophrenia!
(Fatemi!et!al.,!2013);!(ii)!Hu!and!colleagues,!who!highlighted!the!importance!of!signalling!molecules!
such!as!Preso1,!that!endogenously!regulate!mGluR5!signalling!and!function!(Hu!et!al.,!2012);!(iii)!and!
lastly,!Timms!and!colleagues,!who!demonstrated!that!mGluR5!dysregulations!might!originate!within!
the!GRM5!gene!to!disrupt!downstream!proteinSprotein!interactions!with!molecules!that!endogenousS
ly!regulate!mGluR5,!as!well!as!the!presence!of!genetic!variations!within!GRM5!in!some!patients!that!
could!potentially!alter!glutamate!sensitivity!(Timms!et!al.,!2013).!Considering!the!newly!available!evS
idence,! the! subsequent! studies! in! this! thesis! aimed! to! specifically! determine! whether! mGluR5! was!
dysregulated!in!two!critical!brain!regions!involved!in!schizophrenia!pathology!(the!DLPFC!and!CA1),!
and!whether!dysregulation!of!mGluR5!might!originate!within!the!GRM5!gene.!!
!
Building!on!the!results!from!Matosin!et!al.!(2013)!and!Chapter!2!(Matosin!et!al.,!2014)!that!indicated!
unaltered!mGluR5!binding!in!the!DLPFC!and!ACC!regions!in!schizophrenia,!the!findings!in!Chapters!3!
and!4!demonstrate!that!there!are!wider!dysregulations!occurring!within!the!mGluR5!system!not!deS
tectable!by!prior!binding!studies.!In!the!DLPFC!(Chapter!3),!although!there!was!no!change!in!mGluR5!
mRNA! expression,! a! significant! increase! in! mGluR5! protein! (total! and! dimer! measures)! was! found.!
These! measures! were! significantly! correlated! in! control! subjects,! but! not! in! schizophrenia! subjects.!
Further,!marked!reductions!in!Norbin,!Tamalin!and!Preso1!were!also!detected!in!the!DLPFC,!and!theS
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se!were!significantly!associated!with!mGluR5!protein!expression!in!control!subjects!but!not!in!schizS
ophrenia! subjects.! In! Chapter! 4,! a! consistent! increase! in! mGluR5! (total,! monomer! and! dimer!
measures)!was!found!in!the!hippocampal!CA1!region!in!schizophrenia!subjects.!Contrasingly!in!this!
region,! protein! levels! of! all! measured! mGluR5! endogenous! regulators! were! significantly! increased,!
and! displayed! differential! correlations! with! mGluR5! protein! levels,! compared! to! the! results! in! the!
DLPFC.!Additionally,!although!mGluR5!mRNA!measures!were!not!included!in!the!scope!of!this!study,!
mGluR5!expression!was!previously!reported!to!be!unaltered!in!the!CA1!region,!albeit!in!a!small!coS
hort! (n=5;! Ohnuma! et! al.,! 2000b).! These! findings! suggest! that! alterations! to! mGluR5! synthesis! and!
stability!within!the!DLPFC!likely!extend!to!the!CA1!region.!!
!
With!regards!to!the!exact!mechanism!underlying!the!dysregulation!of!mGluR5,!hypotheses!have!been!
suggested! throughout! the! endSofSchapter! discussions! in! Chapters! 2S5.! In! addition! to! the! proposed!
alteration! of! mGluR5! synthesis! and! stability,! the! observed! alterations! of! the! endogenous! regulators!
Norbin,!Tamalin!and!Preso1,!lend!to!the!possibility!of!disruption!to!mGluR5!signalling,!trafficking!and!
internalisation,!which!are!processes!critically!controlled!by!these!proteins!(Hu!et!al.,!2012;!Kitano!et!
al.,! 2003;! Wang! et! al.,! 2009).! In! this! regard,! the! lack! of! change! in! mGluR5! binding! (Matosin! et! al.,!
2013;!Matosin!et!al.,!2014),!in!addition!to!evidence!that!mGluR5!trafficking!might!be!impaired!(due!to!
alterations!in!trafficking!molecules!Norbin!and!Tamalin,!Chapters!3!and!4),!might!be!indicative!of!inS
tracellular!retention!of!mGluR5;!this!is!considering!binding!studies!likely!measure!cellSsurface!recepS
tors!only.!As!GSprotein!coupled!receptor!dimerisation!occurs!soon!after!biosynthesis,!it!is!likely!that!
the!captive!mGluR5!are!in!the!dimer!form!(see!Chapter!3).!A!growing!body!of!evidence!indicates!that!
mGluR5!proteins!are!only!functional!in!the!form!of!disulfideSlinked!dimers!(El!Moustaine!et!al.,!2012;!
Romano!et!al.,!1996),!suggesting!an!increase!in!mGluR5!dimers!represents!an!increase!in!functional!
mGluR5! units! in! the! present! study.! However,! considering! reduced! mGluR5! signalling! (by! mGluR5!
knockout!or!pharmacological!antagonism)!produces!schizophreniaSlike!behaviors,!and!mGluR5!PAMs!
have!therapeutic!efficacy!in!preclinical!rodent!models!(see!Matosin!and!Newell,!2013),!I!hypothesise!
a!model!of!mGluR5!dysregulation!in!which!higher!protein!expression!and!dimer!units!does!not!repreS
sent!increased!activity!and/or!function!in!the!schizophrenia!brain,!but!rather,!alterations!to!mGluR5!
localisation! (Chapter! 3,! Figure! 4a! and! b)! and! also! signalling! (Chapter! 3,! Figure! 4a! and! c);! however,!
further! studies! investigating! the! expression! of! mGluR5! mRNA/protein! within! specific! cellular! comS
partments!will!be!necessary.!
!
It! should! also! be! considered! that! regulation! (and! subsequent! dysregulation)! of! mGluR5! is! likely!
brainSregion!specific.!Unlike!the!DLPFC!where!protein!levels!of!mGluR5!signalling!partners!were!deS
creased! (Chapter! 3),! increased! levels! of! expression! of! these! same! proteins! were! observed! in! CA1!
(Chapter! 4).! Additionally! in! CA1,! there! was! no! correlation! between! mGluR5! and! mGluR5! signaling!
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partners!in!control!subjects!in!this!region!whereas!strong!correlations!were!present!in!the!DLPFC!in!
control!subjects.!This!suggests!the!existence!of!fundamental!differences!in!mGluR5!regulation!in!the!
cortex!compared!to!hippocampal!regions!irrespective!of!diseased!state.!Although!both!the!prefrontal!
cortex! and! hippocampus! are! involved! in! memory! and! learning! tasks,! the! differing! cell! populations,!
network! structures! and! functions! of! these! regions! support! that! the! regulation! of! mGluR5! in! these!
networks!may!also!differ!(Otani,!2004;!Schobel!et!al.,!2009;!Yoon!et!al.,!2008).!!
!
The! observed! changes! to! mGluR5! could! also! represent! a! compensatory! response! due! to! wider!
dysregulation!of!the!glutamate!system!(Chapter!3).!For!example,!considering!the!NMDAR!hypofuncS
tion! hypothesis! of! schizophrenia,! and! evidence! that! expression! of! the! NMDAR! is! decreased! in! the!
DLPFC!of!these!same!schizophrenia!subjects!(Weickert!et!al.,!2012),!mGluR5!could!be!maintained!at!a!
high! levels! on! cortical! neurons! to! account! for! potential! NMDAR! signalling! deficits,! at! least! in! these!
regions.! Furthermore! in! schizophrenia,! it! has! been! suggested! that! regionSdependent! alterations! in!
glutamate!are!present,!with!reduced!glutamatergic!function!in!the!cortex!coupled!with!hyperglutamaS
tergic!function!in!the!hippocampus!(Ohnuma!et!al.,!2000b).!Reflectively,!ionotropic!glutamate!recepS
tors! in! these! regions! are! reported! to! be! differentially! regulated! in! subjects! with! schizophrenia;! for!
example,! the! majority! of! evidence! indicates! alterations! to! the! αSaminoS3ShydroxyS5SmethylS4S
isoxazolepropionic! acid! receptor! (AMPAR)! are! specific! to! the! hippocampus,! whilst! NMDAR! alteraS
tions! are! primarily! observed! in! cortical! regions! (MeadorSWoodruff! and! Healy,! 2000).! As! mGluR5!
modulates!both!these!receptor!subtypes,!the!reasons!for!regional!differences!in!the!relationships!of!
mGluR5! with! its! signalling! partners! might! be! due! to! differential! regulation! of! glutamate! and! ionoS
tropic!glutamate!receptors!in!cortical!compared!to!hippocampal!brain!regions.!Additionally,!mGluR5!
exists!as!three!differently!sized!isoforms!with!varying!length!of!the!intracellular!CSterminus!and!funcS
tions!(Newell!and!Matosin,!2014).!These!isoforms!with!differing!functions!are!reportedly!expressed!
differentially!across!brain!regions,!such!as!the!hippocampus!and!cerebellum!(Malherbe!et!al.,!2002).!
As! previous! studies! have! not! individually! measured! mGluR5! isoforms,! it! is! possible! that! whilst! no!
change!was!detected!in!mRNA!levels!overall,!there!may!be!isoformSdependent!differences,!and!future!
studies!are!required!to!explore!isoformSspecific!differences.!Thus,!it!will!be!critical!for!future!studies!
to!uncover!how!mGluR5!is!regulated!differently!in!different!brain!regions.!!
!
Additionally,!the!results!from!Matosin!et!al.!(2013),!Chapter!3!and!Chapter!4!provide!substantial!eviS
dence!that!shortSterm!(8!days),!mediumSterm!(15!days)!or!longSterm!exposure!(35!days)!to!commonS
ly!used!APD!agents!(haloperidol!and!olanzapine)!do!not!influence!the!mGluR5!system,!suggesting!that!
the! findings! from! these! postmortem! studies! are! unlikely! to! be! confounded! by! antemortem! medicaS
tion!history.!However,!the!‘longSterm’!treatment!period!used!in!the!context!of!these!studies!is!compaS
rable!to!subchronic!treatment,!considering!more!recent!studies!examining!the!effects!of!APDs!on!moS
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lecular!systems!have!employed!significantly!longer!(chronic)!treatment!periods!used!by!others!in!the!
field!(e.g.!12!weeks!treatment!period!was!employed!by!!Deng!et!al.,!2015);!thus!the!effects!of!APD!on!
mGluR5!should!be!confirmed!by!future!studies!in!a!model!of!chronic!exposure.!
!
In!Chapter!5,!analyses!of!SNPs!within!the!3’!UTR!region!of!GRM5!support!that!mGluR5!is!dysregulated!
in!schizophrenia,!and!provides!additional!information!suggesting!this!dysregulation!might!arise!from!
variation!at!the!geneSlevel.!These!findings!provide!strong!support!that!GRM5!is!associated!with!schizS
ophrenia,!and!particularly!the!cognitive!deficits!associated!with!the!disorder.!This!study!is!the!first!to!
bridge! pathological! findings! in! mGluR5! with! clinical! measures! in! humans,! providing! invaluable! inS
sight!into!the!potential!mechanisms!involved!in!mGluR5!dysregulation!and!its!consequences.!HowevS
er,!it!is!important!to!note!that!all!findings!in!Chapter!5!were!genderSspecific,!suggesting!GRM5!may!
operate!in!a!sexSspecific!manner.!Thus,!whilst!the!association!of!GRM5,!cognition!and!schizophrenia!is!
not!surprising!based!on!the!extensive!evidence!from!animal!models!of!a!role!for!mGluR5!in!this!conS
text! (Matosin! and! Newell,! 2013),! the! genderSspecific! findings! from! this! study! provide! the! first! eviS
dence!that!mGluR5!may!be!affected!differently!in!men!and!women.!
!
!

6.2!!

Further!considerations,!limitations!and!recommendations!for!future!research!

Collectively,! the! results! from! the! studies! presented! in! this! thesis! provide! evidence! from! the! gene,!
mRNA!and!protein!levels!that!strongly!support!a!model!of!mGluR5!dysregulation!in!the!pathophysiS
ology! of! schizophrenia.! However,! there! are! numerous! issues! that! must! be! further! deliberated,! and!
caution! taken! with! the! interpretation! of! these! results! as! the! present! studies! do! not! uncover! all! the!
details!necessary!to!draw!absolute!conclusions.!!
!
As!postmortem!human!brain!tissue!cohorts!are!a!limited!resource,!it!is!a!significant!strength!of!the!
current! body! of! work! that! three! brain! regions! of! interest! were! examined! across! three! independent!
postmortem! cohorts! covering! four! major! neuropsychiatric! disorders! (schizophrenia,! bipolar! disorS
der,!major!depression!without!psychosis,!major!depression!with!psychosis).!However!these!strengths!
also!engender!several!caveats;!specifically,!the!postmortem!studies!within!this!thesis!are!inconsistent!
with!regards!to!the!experiments!performed,!brain!regions!studied!and!cohorts!employed!with!these!
factors!varying!across!Chapters!2!to!4.!This!can!lead!to!holes!in!the!current!understanding.!For!examS
ple,! it! is! unclear! whether! the! conflicting! results! from! Chapter! 2,! in! which! mGluR5! binding! is! unalS
tered,!and!Chapters!3!and!4,!where!mGluR5!total!protein!levels!are!significantly!increased,!is!driven!
by!cohortSspecific!differences!or!brain!region!heterogeneity!of!expression.!However!considering!my!
previous!binding!study!also!detected!no!change!in!mGluR5!binding!in!the!closely!related!DLPFC!reS
gion! (Matosin! et! al.,! 2013),! it! is! more! likely! that! these! differences! are! a! result! of! different! experiS
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mental!methods!(binding!versus!immunoblot),!although!replication!of!these!experimental!methods!in!
wellSpowered!independent!cohorts!of!identical!brainSregions!is!necessary.!Notably,!the!subjects!studS
ied!in!Chapter!4!(CA1)!are!a!subset!of!the!same!subjects!examined!in!Chapter!3!(DLPFC),!and!mGluR5!
was!uniformly!increased!in!both!these!regions,!reducing!the!chance!of!cohortSspecific!differences.!
!
One!of!the!limitations!of!previous!work,!as!previously!noted,!has!been!the!small!sample!sizes!within!
earlier!studies.!This!issue!also!encroaches!on!my!works!within!Chapters!2!(n=12S15/group),!4!(n=20)!
and!5!(n=236/group),!particularly!when!sexSwise!statistics!were!performed.!These!issues!are!inherS
ent!in!the!field!of!postmortem!human!brain!analyses,!considering!their!increasingly!limited!availabilS
ity!due!to!the!field’s!improved!understanding!of!developing!methodically!rigorous!cohorts!that!are!
strictly!matched!for!pH,!postmortem!interval,!age!of!death,!and!other!demographic!and!clinical!variaS
bles;!it!thus!requires!many!resources!and!a!lot!of!time!to!develop!high!quality!cohorts,!reducing!their!
availability!and!size.!For!the!postmortem!brain!analyses!in!this!thesis,!power!calculations!based!on!
Matosin!et!al.!(2013)!suggested!that!a!sample!size!of!20!subjects!per!group!is!required!to!reliably!deS
tect!molecular!changes!as!small!as!5%!with!95%!confidence.!When!investigating!differences!between!
mRNA/protein!measurements!in!all!schizophrenia!subjects!compared!to!controls!in!the!DLPFC!and!
CA1!(Chapter!3!and!4),!there!was!sufficient!power!to!reliably!detect!alterations!(n>20).!However,!in!
instances!when!subjects!were!reclassified,!such!as!in!the!case!of!gender!within!diagnostic!groups!
(schizophrenia/control),!power!was!reduced.!For!example,!in!Chapter!4,!although!a!gender!effect!was!
observed!overall!whereby!mGluR5!protein!levels!were!reduced!in!male!(n=28)!compared!to!female!
(n=11)!subjects,!the!study!was!slightly!underpowered!for!the!mean!differences!observed,!requiring!
12!extra!female!subjects!(power!level!0.8;!power!analysis!via:!
http://www.biomath.info/power/ttest.htm)!to!detect!a!significant!change!within!schizophreS
nia/control!groups.!Similarly!in!Chapter!5,!a!power!calculation!indicates!that!for!the!smaller!of!
the!two!cohorts,!a!sample!size!of!268!cases!(536!alleles)!with!a!MAF!of!0.14!has!>90%!has!a!priS
ori!power!to!detect!a!significant!allelic!association!conferring!an!odds!ratio!of!1.5!or!greater.!Although!
the!caseScontrol!cohort!possessed!sufficient!power!overall,!when!separated!for!gender!and/or!GoMS
subtype!analyses,!the!power!was!reduced.!Thus,!it!is!imperative!that!future!studies!specifically!invesS
tigating!mGluR5/GRM5!should!consider!that!alterations!might!be!genderSdependent,!and!account!for!
this!series!of!analyses!when!choosing!the!sample!size!in!the!study!design.!
!
Considering!that!the!evidence!from!this!collection!of!studies!suggests!that!mGluR5!is!dysregulated!in!
the! pathophysiology! of! schizophrenia,! these! findings! have! numerous! implications! for! future! novel!
mGluR5Stargeting!therapies.!Traditionally,!the!identification!of!pathological!alterations!in!mGluR5!is!
considered! supportive! of! the! use! of! therapeutics! directed! at! mGluR5! to! correct! these! dysfunctions.!
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However,! evidence! suggests! there! is! a! possibility! that! currently! developed! mGluR5Stargeted! drugs!
may!not!be!of!therapeutic!value:!
•

Many!drugs!targeting!mGluR5!are!not!membrane!permeable,!and!depend!on!cellSsurface!exS
pression!of!mGluR5;!thus,!it!must!be!confirmed!whether!there!are!available!surface!targets!for!
mGluR5!in!schizophrenia!regions!involved!in!the!pathology.!Whilst!the!binding!studies!previS
ously!reported!suggest!the!availability!of!binding!sites!at!least!in!the!DLPFC!and!ACC!(Matosin!
et!al.,!2013;!Matosin!et!al.,!2014),!this!should!be!confirmed!in!cellSmembrane!fractions!from!
postmortem!samples.!!

•

There!is!extensive!evidence!that!mGluR5!is!subjected!to!“location!bias”,!whereby!60S90%!of!
mGluR5!are!reportedly!located!within!intracellular!membranes.!Purgert!and!colleagues!pubS
lished!an!interesting!study!earlier!this!year,!demonstrating!that!mGluR5!is!able!to!signal!from!
these! intracellular! locations,! where! they! play! a! particularly! important! role! in! modulation! of!
hippocampal!synaptic!plasticity!(Purgert!et!al.,!2014).!Considering!this!evidence,!it!is!critical!
for!future!studies!to!determine!whether!novel!mGluR5Stargeting!drugs!should!in!fact!be!deS
signed!to!target!intracellular!mGluR5.!

•

The!previously!discussed!alterations!to!mGluR5!localisation,!dimerisation,!glutamate!insensiS
tivity!(as!hypothesised!by!Timms!et!al.,!2013),!or!disrupted!proteinSprotein!interactions!with!
endogenous!regulators!known!to!modulate!mGluR5!function!(such!as!Norbin!and!Preso1!that!
modulate!mGluR5!signalling,!and!evidence!to!support!this!hypothesis!in!Chapters!3S5)!might!
render! mGluR5! units! present,! but! not! functional.! Even! considering! this! possibility,! there! is!
still!potential!for!the!use!of!pharmacological!agents!targeted!at!the!mGluR5!system.!However,!
first,!future!pathological!studies!are!required!to!determine!the!nature!of!these!alterations!so!
that! the! appropriate! therapeutics! may! be! developed;! for! example,! if! trafficking! deficits! in!
mGluR5! are! confirmed,! these! deficits! may! be! more! successfully! treated! with! pharmacoperS
ones!rather!than!allosteric!modulators!(including!PAMs).!It!is!recommended!that!future!studS
ies!uncover!the!precise!nature!of!mGluR5!dysfunction,!so!that!the!appropriate!types!of!theraS
peutics!may!be!developed.!

!

6.3!!

Conclusion!!

In!addition!to!the!widely!reported!role!of!glutamate!in!the!emergence!of!cognitive!deficits!in!schizoS
phrenia,!and!animal!studies!demonstrating!that!mGluR5!critically!controls!the!mechanisms!underlyS
ing!cognitive!function,!the!findings!from!this!thesis!provide!the!first!evidence!of!mGluR5!dysregulaS
tion! in! schizophrenia.! These! findings! significantly! contribute! to! the! existing! body! of! evidence! that!
mGluR5!is!involved!in!the!pathophysiology!of!the!disorder.!Furthermore,!these!findings!support!the!
development!of!agents!that!modulate!mGluR5!regulation!and/or!signalling!to!treat!the!cognitive!dysS
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functions!in!patients!with!schizophrenia,!although!additional!studies!are!required!to!first!uncover!the!
consequences!of!these!alterations.!!
!
The!present!study!offers!a!substantial!contribution!to!the!existing!knowledge!of!the!role!of!mGluR5!in!
the! pathophysiology! of! schizophrenia.! Furthermore,! in! line! with! the! existing! evidence! from! animal!
studies!that!mGluR5!alterations!induce!deficits!in!synaptic!plasticity,!the!results!form!Chapter!5!show,!
for! the! first! time,! that! GRM5)has! a! modulatory! effect! on! cognitive! function! in! humans.! As! mGluR5S
targeting!drugs!have!cognitiveSenhancing!properties!in!preclinical!paradigms,!and!current!APDs!minS
imally! treat! the! cognitive! deficits! associated! with! schizophrenia,! these! studies! collectively! suggest!
that!mGluR5!may!offer!value!as!an!adjunct!cognitiveSenhancing!drug!in!those!patients!suffering!from!
the!cognitive!aspects!of!the!disorder.!However,!due!to!the!heterogeneity!of!schizophrenia,!an!individS
ualised!treatment!approach!will!likely!be!necessary.!Therefore!future!studies!will!be!required!to!idenS
tify!the!patient!subset!that!will!benefit!from!mGluR5Stargeted!treatments.!!
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2.#Supplementary#Materials,#Chapter#3#

Supplementary#Fig.#1#Full(length!immunoblots!for!(a)!mGluR5,!(b)!Norbin,!(c)!Tamalin,!and!(d)!Preso1!
(A.!with!no!peptide,!B.!with!blocking!peptide).!mGluR5!(a)!appeared!as!2!distinct!bands!at!135kDa!(mon(
omer)!and!270kDa!(dimer)!and!these!bands!have!previously!been!shown!to!be!specific!for!mGluR5!in!
HEK!cells!transfected!with!mGluR5!(www.abcam.com/Metabtropic(Glutamate(Receptor(5(antibody(
ab27190).!Norbin!(b)!and!Tamalin!(c)!were!reliably!detected!as!single!bands!at!the!expected!molecular!
weights!(79kDa!and!96kDa!respectively)!with!no!non(specific!binding.!The!Preso1!antibody!(Santa!Cruz!
sc(242862)!produced!several!bands!at!various!molecular!weights!(d);!A!single!specific!band!was!verified!
at!144kDa!by!peptide!pre(absorption/neutralization,and!this!band!was!quantified.The!representation!of!
ß(actin!(e);!is!taken!from!the!mGluR5!immunoblot!which!was!reprobed!with!ß(actin!as!a!loading!control.!
ß(actin!was!measured!in!the!same!way!for!all!immunoblots!in!this!study.!
!
!
Supplementary#Methods:#Determination#of#Preso1#specificity#by#peptide#preAabsorption#(FRMPD4#
Antibody,#Santa#Cruz:#scA242862#and#scA242862#P)#
Peptide!pre(absorption/neutralization!was!performed!according!to!the!protocol!described!by!Santa!Cruz!
(http://www.scbt.com/protocols.html?protocol=peptide_neutralization).!The!highest!concentration!of!
antibody!dilution!for!which!a!consistently!positive!result!was!achieved,was!determined!to!be!1:1000.!For!
blocking/competition,!10µL!of!antibody,!50µL!of!peptide!and!500µL!of!PBS,!was!combined!and!incubated!
for!2!hours!at!room!temperature.!The!antibody/peptide!solution!was!subsequently!diluted!up!to!10mL!
with!0.5%!skim!milk!in!PBST,!and!applied!to!membranes!containing!15µg!of!electrophoresed!protein!
from!the!rat!prefrontal!cortex.!These!immunoblots!were!prepared!and!electrophoresed!as!described!in!
the!main!methods.!
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Supplementary#Table#1.#Immunoblot!conditions:!all!immunoblots!were!run!on!bis(trispolyacrymalide!
gels!(4(12%!Bis(Tris,!BioRad),!at!a!loading!concentration!of!5μg!(human)!or!10µg!(rat)!of!total!protein!per!
lane.!Samples!were!reduced!with!laemmli!buffer!containing!ß(mercaptoethanol.!
Protein

Buffer

Block

Denaturing

mGluR5

PBST

Skim milk

95˚C for 5min

Tamalin

PBST

BSA

95˚C for 5min

Norbin

PBST

BSA

95˚C for 5min

Preso1

PBST

BSA

95˚C for 5min

ß-actin

As for primary antibody

1o antibody
Dilution (huTemp.
man, rat)
1:250,
4o C
1:500
1:100,
4o C
1:1000
1:500,
4o C
1:500
1:100,
4o C
1:1000
1:5000,
RT
1:5000

2o antibody
Dilution Temp

Time

Rabbit

1:3000

RT

1 hr

16 hr

Rabbit

1:3000

RT

1 hr

16 hr

Rabbit

1:3000

RT

1 hr

16 hr

Goat

1:3000

RT

1 hr

1 hr

Mouse

1:3000

RT

1 hr

Time

Type

16 hr

Abbreviations:##BSA:!Bovine!serum!albumin;!mGluR5:!metabotropic!glutamate!receptor!5;!PBST:!phos(
phate(buffered!saline!containing!Tween(20;!RT:!room!temperature.!
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Supplementary,Table,2.!Spearman's!Correlations!for!continuous!clinical!and!demographic!variables!and!mGluR5!(mRNA,!total!and!dimer),!Norbin,!Tamalin!and!Preso1!protein!
levels!in!the!postmortem!dorsolateral!prefrontal!cortex.!Significant!values!(p<0.05)!are!highlighted!in!bold.
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All subjects
Controls
Schizophrenia
Variable
mGluR5 mGluR5 mGluR5 Norbin Tamalin Preso1 mGluR5 mGluR5 mGluR5 Norbin Tamalin Preso1 mGluR5 mGluR5 mGluR5 Norbin Tamalin Preso1
mRNA (total) (dimer)
mRNA (total) (dimer)
mRNA (total) (dimer)
Brain pH
r = 0.267 r = 0.001 r = 0.006 r = 0.123 r = -0.021 r = -0.062 r = 0.137 r = 0.002 r = -0.133 r = -0.028 r = -0.150 r = 0.110 r = 0.351 r = 0.063 r = 0.176 r = 0.175 r = 0.096 r = -0.078
p = 0.021 p = 0.994 p = 0.960 p = 0.297 p = 0.860 p = 0.598 p = 0.420 p = 0.992 p = 0.431 p = 0.870 p = 0.375 p = 0.517 p = 0.033 p = 0.714 p = 0.303 p = 0.301 p = 0.574 p = 0.645
Age at Death
r = -0.242 r = -0.037 r = 0.012 r = -0.009 r = 0.175 r = 0.108 r = -0.417 r = -0.110 r = 0.103 r = 0.171 r = 0.353 r = 0.218 r = -0.106 r = 0.192 r = 0.095 r = -0.193 r = 0.012 r = 0.009
p = 0.037 p = 0.758 p = 0.920 p = 0.939 p = 0.136 p = 0.358 p = 0.010 p = 0.524 p = 0.543 p = 0.311 p = 0.032 p = 0.194 p = 0.531 p = 0.261 p = 0.580 p = 0.253 p = 0.946 p = 0.959
RNA integrity number r = 0.229 r = 0.038 r = 0.134 r = 0.122 r = 0.069 r = 0.098 r = 0.050 r = -0.061 r = 0.047 r = 0.046 r = -0.102 r = -0.020 r = 0.437 r = 0.176 r = 0.355 r = 0.312 r = 0.305 r = 0.265
p = 0.050 p = 0.748 p = 0.258 p = 0.301 p = 0.560 p = 0.408 p = 0.767 p = 0.724 p = 0.784 p = 0.788 p = 0.547 p = 0.905 p = 0.007 p = 0.306 p = 0.034 p = 0.060 p = 0.066 p = 0.113
Post-mortem interval r = 0.124 r = -0.055 r = 0.174 r = 0.132 r = 0.102 r = 0.002 r = -0.017 r = -0.179 r = -0.081 r = 0.155 r = 0.184 r = 0.119 r = 0.213 r = -0.066 r = 0.273 r = -0.259 r = 0.083 r = -0.027
p = 0.292 p = 0.649 p = 0.140 p = 0.262 p = 0.385 p = 0.987 p = 0.921 p =0.297 p = 0.636 p = 0.358 p = 0.275 p = 0.483 p = 0.205 p =0.703 p = 0.107 p = 0.122 p = 0.623 p = 0.874
Freezer storage time r = 0.043 r =0.221 r = 0.146 r = -0.132 r = -0.446 r = -0.369 r = 0.301 r = 0.501 r = 0.275 r = -0.348 r = -0.533 r = -0.391 r = -0.254 r = -0.373 r = -0.446 r = -0.375 r = -0.242 r = -0.245
p = 0.715 p = 0.062 p = 0.217 p = 0.001 p< 0.001 p = 0.001 p = 0.070 p =0.002 p = 0.099 p = 0.035 p< 0.001 p = 0.017 p = 0.129 p =0.025 p = 0.006 p = 0.022 p = 0.149 p = 0.145
Brain weight
r = 0.270 r = -0.009 r = -0.114 r = 0.120 r = 0.065 r = 0.039 r = 0.181 r = -0.022 r = -0.189 r = 0.055 r = -0.001 r = 0.110 r = 0.398 r = 0.057 r = -0.061 r = -0.023 r = 0.084 r = -0.103
p = 0.020 p = 0.940 p = 0.339 p = 0.309 p = 0.581 p = 0.740 p = 0.282 p =0.899 p = 0.263 p = 0.747 p = 0.993 p = 0.515 p = 0.015 p =0.470 p = 0.724 p = 0.895 p = 0.620 p = 0.543
Age of disease onset
r = -0.213 r = 0.130 r = -0.072 r = -0.362 r = -0.108 r = -0.364
p = 0.206 p =0.450 p = 0.674 p = 0.028 p = 0.524 p = 0.027
Duration of illness
r = -0.009 r = 0.120 r = 0.082 r = -0.076 r = -0.079 r = 0.172
p = 0.959 p =0.486 p = 0.634 p = 0.654 p = 0.641 p = 0.308
r = 0.038 r = 0.015 p = 0.051 r = 0.043 r = 0.037 r = -0.030
p = 0.823 p =0.932 p = 0.768 p = 0.802 p = 0.826 p = 0.861
Lifetime antipsychotic
drug medication
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Supplementary,Table,3$Spearman's$correlations$for$associations$between$mGluR5$(total$and$dimer$protein$
measures,$and$mRNA)$and$novel$mGluR5$signaling$partners,$Norbin,$Tamalin$and$Preso1$protein$levels$in$
the$dorsolateral$prefrontal$cortex$of$the$postmortem$schizophrenia$brain.$Significant$values$(p<0.05)$are$
highlighted$in$bold.$
$
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$
mGluR5 total
mGluR5 dimer
mGluR5 expression
CONTROL
(protein)
(protein)
(mRNA)
mGluR5(tot)
r = 0.512
r = 0.361
(protein)
p = 0.001
p = 0.030
mGluR5(dim)
r = 0.512
r = 0.050
(protein)
p = 0.001
p = 0.770
mGluR5
r = 0.361
r = 0.050
(mRNA)
p = 0.030
p = 0.770
Norbin
r = -0.657
r = -0.227
r = -0.500
(protein)
p< 0.001
p = 0.018
p = 0.002
Tamalin
r = -0.560
r = -0.196
r = -0.470
(protein)
p< 0.001
p = 0.254
p = 0.003
Preso1
r = -0.428
r = -0.367
r = -0.372
(protein)
p = 0.009
p = 0.026
p = 0.023
SCHIZOPHRENIA
mGluR5(tot)
(protein)
mGluR5(dim)
(protein)
mGluR5
(mRNA)
Norbin
(protein)
Tamalin
(protein)
Preso1
(protein)

mGluR5 total
(protein)
r = 0.608
p< 0.001
r = 0.059
p = 0.732
r = 0.096
p = 0.578
r = 0.202
p = 0.238
r = 0.080
p = 0.644

mGluR5 dimer
(protein)
r = 0.608
p< 0.001
r = 0.125
p = 0.468
r = 0.388
p = 0.019
r = 0.175
p = 0.307
r = -0.069
p = 0.689

mGluR5 expression
(mRNA)
r = 0.059
p = 0.732
r = 0.125
p = 0.468
r = 0.466
p = 0.004
r = 0.051
p = 0.764
r = -0.009
p = 0.960
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Abstract

Metabotropic glutamate receptor 5 (mGluR5) is involved in hippocampal-dependent learning and
memory, which are processes disrupted in schizophrenia. Recent evidence from human genetic and
animal studies suggests that the regulation of mGluR5, including its interaction with trafficking molecules, may be altered in the disorder. However there have been no investigations of hippocampal
mGluR5 or mGluR5 trafficking molecules in the postmortem schizophrenia brain to confirm this. In
the present study, we investigated whether protein expression of mGluR5, as well as Norbin and Tamalin (modulators of mGluR5 signalling and trafficking), might be altered in the schizophrenia brain,
using postmortem samples from the hippocampal CA1 region of schizophrenia subjects and matched
controls (n=20/group). Protein levels of mGluR5 (total: 42%, p<0.001; monomer: 25%, p=0.011; dimer: 52%, p< 0.001) and mGluR5 trafficking molecules (Norbin: 47%, p<0.001; Tamalin: 34%,
p=0.009) were significantly higher in schizophrenia subjects compared to controls. To determine any
influence of antipsychotic drug treatment, all proteins were also correlated with lifetime chlorpromazine equivalents in patients, and separately measured in the hippocampus of rats exposed to haloperidol or olanzapine treatment. mGluR5 was negatively correlated with lifetime antipsychotic drug exposure in schizophrenia patients, suggesting antipsychotic drugs could reduce mGluR5 protein in
schizophrenia subjects. In contrast, mGluR5 and mGluR5 trafficking molecules were not altered in
the hippocampus of antipsychotic drug treated rats. This investigation provides strong support for the
hypothesis that mGluR5 is involved in the pathology of schizophrenia, and that alterations to mGluR5
trafficking might contribute to the hippocampal-dependent cognitive dysfunctions associated with this
disorder.

Keywords: mGluR5, Hippocampus, Norbin, Tamalin, Trafficking, Schizophrenia

Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; APD, antipsychotic
drug; DLPFC, Dorsolateral prefrontal cortex; mGluR5, metabotropic glutamate receptor 5; NMDAR,
N-methyl-D-aspartate receptor; PAM, positive allosteric modulator; PFC, prefrontal cortex; PMI,
postmortem interval.
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1. Introduction

$
Metabotropic glutamate receptor subtype 5 (mGluR5) is a postsynaptic G-protein coupled receptor
(GPCR), best known for its ability to modulate postsynaptic currents induced by the ionotropic Nmethyl-D-aspartate glutamate receptor (NMDAR; Matosin and Newell, 2013). A substantial body of
evidence indicates that mGluR5 is critically involved in hippocampal-dependent learning and
memory. Specifically, several studies have reported that hippocampal mGluR5 activity is important
for long-term potentiation (LTP) and long-term depression (LTD), molecular mechanisms underpinning synaptic plasticity (see Mukherjee and Manahan-Vaughan, 2013). mGluR5 knockout mice display reduced LTP, specifically in the hippocampal cornu ammonis 1 (CA1) region, as well as deficits
in spatial learning and memory (Lu et al., 1997). Chronic mGluR5 antagonism in rats similarly induces deficits in LTP in the CA1 region, which correlates with reduced hippocampal mGluR5 protein
levels and poorer working and reference memory (Manahan-Vaughan and Braunewell, 2005). Accordingly, mGluR5 positive allosteric modulators (PAMs) enhance the balance of hippocampal LTP
and LTD at CA1 synapses, and consequently improve spatial learning in mice (Ayala et al., 2009).
Notably, very recent evidence suggests localisation of mGluR5 in this region might modulate the direction or balance of synaptic plasticity (e.g. LTP versus LTD; Purgert et al., 2014).

Despite extensive examination in animal models, the status of hippocampal mGluR5 protein in patients with schizophrenia is largely unknown. Only one study has previously investigated mGluR5
mRNA expression in the hippocampus of schizophrenia subjects (in a small postmortem cohort of 5
schizophrenia subjects and 6 controls), reporting decreased mGluR5 expression in the parahippocampal gyrus, and no alterations in the dentate gyrus, CA1, CA3 or CA4 (Ohnuma et al., 2000). Based on
studies indicating the importance of mGluR5 in synaptic plasticity, including reports that suggest
mGluR5 deficits lead to schizophrenia-like cognitive dysfunctions, it is important to extend on these
works and thoroughly investigate whether hippocampal mGluR5 is altered in schizophrenia, specifically at the protein level, as this might contribute to the manifestation of learning and memory deficits
observed in patients with schizophrenia.

Accumulating evidence indicates the importance of mGluR5 protein-protein interactions in the regulation of mGluR5 trafficking, internalisation and signalling (Enz, 2007). The first discovered modulator of mGluR5 was Homer1 (Brakeman et al., 1997), which has since been extensively studied in the
context of schizophrenia (Szumlinski et al., 2006). Both Homer1 protein and gene are reported as altered in, or associated with, schizophrenia (Engmann et al., 2011; Spellmann et al., 2011). However,
in recent years, other molecules that modulate mGluR5 localisation and trafficking have become apparent. The neuron-specific protein Norbin (neurochondrin) plays a critical role in mGluR5 localisation, and positively regulates mGluR5 signalling. Interestingly, Norbin knockout was found to reduce
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mGluR5-dependent LTP and abolished LTD in CA1 synapses (Wang et al., 2009).$In cultured mouse
hippocampal CA1/CA3 neurons, the multiscaffold protein Tamalin also proved critical to mGluR5
neuritic localisation processes (Kitano et al., 2002) and deletion of the Tamalin binding site on
mGluR5 induced mGluR5 internalisation in cellular assays (Timms et al., 2013). Furthermore, evidence from a schizophrenia pedigree suggests that mGluR5/Tamalin interactions might be disrupted
in the disorder (Timms et al., 2013). As mGluR5 localisation appears to impact on mGluR5 functions
(Purgert et al., 2014), it is important to consider the possibility of altered mGluR5 trafficking in the
context of schizophrenia. However, the status of these mGluR5 trafficking molecules in any neuropsychiatric pathology, including schizophrenia, has not been assessed.

In the present study, we therefore determined whether mGluR5 protein levels are altered in postmortem samples from the CA1 hippocampal region of schizophrenia subjects compared to healthy controls (n=20/group). We further examined protein levels of the mGluR5 trafficking molecules Norbin
and Tamalin, which collectively play an important role in mGluR5 trafficking, internalisation and
signalling (Kitano et al., 2003; Wang et al., 2009). The CA1 region was chosen for examination due
to evidence that mGluR5-mediated LTP might be specific to CA1 synapses (Lu et al., 1997). Subsequently, we ascertained whether any observed changes in protein levels of mGluR5 or its trafficking
molecules were influenced by antipsychotic drug (APD) treatment. For this purpose, we treated rats
with first- and second-generation APDs (haloperidol and olanzapine respectively) and measured hippocampal protein levels of mGluR5, Norbin and Tamalin.

2. Materials and methods

2.1 Human postmortem brain samples and tissue preparation

Postmortem human CA1 samples from 20 control (no history of psychiatric diagnosis) and 20 schizophrenia subjects, diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders
IV (DSM-IV), were obtained from the New South Wales Brain Bank Network (Sydney, Australia).
Subjects were matched according to tissue pH, postmortem interval, RNA integrity number (RIN) and
age at death (Table 1). APD treatment premortem was standardised to a lifetime chlorpromazine
equivalent for each patient, and antidepressant drug treatment history was specified on a qualitative
scale (i.e. yes/no). The samples analysed in this study were derived from a cohort we previously used
to examine mGluR5 (Brodmann's Area 46, n=37/group; Matosin et al., 2013). This work was approved by the Human Research Ethics Committees at the University of Wollongong (HE99/222) and
the University of New South Wales (HREC 07261). Anatomical identification and preparation of this
CA1 tissue has been previously described in detail (Fernandez-Enright et al., 2014).
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2.2 Animal housing, treatment and tissue preparation
To assess the influence of haloperidol and olanzapine on mGluR5 and mGluR5 endogenous regulator
expression, rats were treated with APD medication as previously described (Matosin et al., 2013).
Briefly, adult (10 weeks of age) male Sprague-Dawley rats were purchased from the Animal Resource
Centre (Perth, Australia). Rats were separated into groups according to the 3 treatments and 3 treatment-durations (9 groups; n=6/group). Animals were fed prepared food pellets (sweet cookie dough
containing 62% carbohydrate, 22% protein, 10% vitamins, 6% fibre and minerals) 3 times/day at 8
hour intervals, containing either typical antipsychotic, haloperidol (0.1mg/kg body weight; daily total
0.3mg/kg), or atypical antipsychotic, olanzapine (1mg/kg body weight; daily total 3mg/kg), or vehicle
control (no drug), for short term (8 days), medium term (15 days) and long term (35 days) durations.
Food and water was available ad libitum, and consumption of food pellets was visually validated.
APD doses were chosen to model a clinical setting (Han et al., 2008; Weston-Green et al., 2012).

Forty-eight hours after final treatment, rats were euthanised using carbon dioxide asphyxiation. The
hippocampus (Bregma −2.30 to −5.20; total of dorsal and ventral regions) was dissected on ice, snap
frozen in liquid nitrogen and then stored at -80°C until use. Tissue was homogenised in NP-40 lysis
buffer (Invitrogen, Australia), containing ß-glycerophosphate and pheylmethanesulfonylfluoride and
protease inhibitor cocktail (Sigma). Protein concentration was determined by DC assay (Bio-Rad),
according to the manufacturer’s instructions. All animal experiments in this study were approved by
the University of Wollongong Animal Ethics Committee (AE10/18) and complied with the Australian
Code of Practice for the Care and Use of Animals for Scientific Purposes.

2.3 Immunoblot analyses

Immunoblotting was performed on total homogenates as described previously (Matosin et al., 2013),
with minor modifications optimised for the measurement of each protein of interest. Each lane was
loaded with 5µg (human) or 10µg (animal) of total protein. These protein concentrations were determined to be in the linear range of detection (data not shown). Relative protein densities were determined by immunoblot analyses using polyclonal antibodies as previously reported: mGluR5
[ABCAM ab27190; human 1:250, rat 1:500 (Matosin et al., 2013)], Norbin [ABCAM ab130507; human and rat 1:500), and Tamalin [ABCAM ab30576; human 1:100, rat 1:1000 (Tai et al., 2010)].
mGluR5 monomer was detected at 135kDa whilst the mGluR5 dimer was detected at 270kDa. Individual bands were totalled before normalisation to respective ß-actin and pooled samples to gain a
measure of total mGluR5. Samples were visualised using an enhanced chemiluminescent detection kit
(Bio-Rad). Band density was detected by the Gel Doc 2200 Pro (Carestream Molecular Imaging,
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USA) and quantified with Carestream MI software (v 5.0.4.44, Carestream Molecular Imaging). All
bands were within the limits of saturation. Protein measures were subsequently normalised to their
respective ß-actin density. Experiments and quantification were performed blind to diagnosis (human)
or treatment group (rat).

2.4 Statistical Analyses

Statistical analyses were performed with SPSS software (v19.0). The level of significance was set to
p<0.05 and data are presented as mean±SEM.

2.4.1 Human brain statistical analyses

Distributions of mGluR5 total measures (but not individual monomer or dimer measures) as well as
Norbin and Tamalin were skewed to the right (Kolmogorov-Smirnov; d=0.152-0.246, p<0.001).
Normalised distribution for these proteins was therefore achieved by transforming to the natural logarithm of the relative protein values. Outliers were screened as mean ±2 standard deviations and removed. Analyses of Variance (ANOVA) were used to detect differences in protein expression between diagnostic groups (schizophrenia/control) as well as gender (male/female), hemisphere
(left/right) and antidepressant history (yes/no) for each target. Spearman’s correlations were used to
determine whether sample characteristics (Table 2) were associated with protein measures, and to examine if additional measures of disease characteristics were correlated specifically with the schizophrenia group (lifetime APD history, age of disease onset and duration of illness). Analyses of covariance (ANCOVA) for diagnostic effects on protein expression were subsequently performed, accounting for sample characteristics that were associated with protein measures. Further Spearman’s correlations were performed to determine the strength of associations between mGluR5 measures and its
trafficking molecules in schizophrenia compared to control subjects.

2.4.2 Animal brain statistical analyses

Values for mGluR5 (total) and Norbin were skewed to the right (Kolmogorov-Smirnov; d=0.1030.169, p<0.001), and thus were normalised by converting to the natural logarithm. Protein differences
between treatment (haloperidol/olanzapine/vehicle) and duration (short term/medium term/long term)
were analysed by two-way ANOVA.
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3. Results

3.1 Protein levels of mGluR5 in schizophrenia subjects compared to controls

We detected a robust increase in mGluR5 protein levels in the CA1 region of schizophrenia subjects
compared to controls (total: +42%, F1,37=138.579, p<0.001; monomer: +25%, F1,37=7.194, p=0.011;
dimer: +52%, F1,37= 51.705, p<0.001; Figure 1). Demographic and clinical measures that correlated
significantly with mGluR5 protein levels (Table 2) were assessed for their influence on the data. After
co-varying for freezer storage time and brain pH, which significantly correlated with mGluR5 (total
and dimer), significant differences between schizophrenia and control were maintained (mGluR5 total: F1,35=172.974, p<0.001; mGluR5 dimer: F1,35=59.433, p<0.001). An effect of gender was observed, whereby mGluR5 total protein was decreased in male subjects independent of diagnosis
(F1,37=5.357, p=0.026; -35.5%); however, there was no gender-specific difference in mGluR5 protein
levels within the schizophrenia or control groups, and no hemispheric differences in mGluR5 protein
expression.

3.2 Protein levels of mGluR5 trafficking molecules, Norbin and Tamalin, in schizophrenia subjects
compared to controls

Norbin and Tamalin proteins were identified at the expected molecular weights (79kDa and 96 kDa
respectively; Figure 2). Protein levels of these mGluR5 trafficking molecules were significantly increased in schizophrenia (Figure 2). Specifically, Norbin was increased by 46.7% (F1,37=19.600,
p<0.001) and Tamalin by 34.0% (F1,37=7.630, p=0.009). There were no effects of gender or hemisphere on Norbin or Tamalin. Considering the nature of our results whereby all measured proteins of
interest were increased, we further analysed protein levels of α-tubulin as a negative control to eliminate the possibility of a global protein increase within the schizophrenia samples. Protein levels of αtubulin (05-829, Millipore) were not significantly different between schizophrenia and control subjects (F1,37=1.991, p=0.167), validating our findings of increased mGluR5 and mGluR5 trafficking
molecules.

3.3 Effects of clinical and demographic variables, and premortem medication estimates on protein
measures

Spearman’s correlations were performed to determine any relationships between demographic/clinical
variables and protein levels of mGluR5 (total, monomer and dimer), Norbin and Tamalin (Table 2).
There was a significant correlation between mGluR5 total protein and brain pH in all subjects, but this
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was not maintained in the individual diagnostic groups. There was an effect of freezer storage time on
mGluR5 total and dimer levels. A significant negative correlation was observed between lifetime antipsychotic drug dose and mGluR5 monomer levels in schizophrenia subjects; this association was
also trending for mGluR5 dimer levels. APD measures did not correlate with Norbin or Tamalin protein levels. Lastly, there were no effects of antidepressant medication (yes/no; F17-18≥0.015, p≥0.189)
on mGluR5, Norbin or Tamalin protein levels.

3.4 Relationships of mGluR5 protein (total, monomer and dimer) with Norbin and Tamalin in schizophrenia subjects compared to controls

Spearman’s correlations were performed to determine the presence or loss of associations between
mGluR5 and its trafficking molecules in control and schizophrenia subjects (Table 3). Although
mGluR5 monomer and dimer levels were strongly and positively correlated in both control and schizophrenia subjects (r≥0.790, p≤0.001), there were no correlations between measures of mGluR5 (total,
monomer or dimer) and its trafficking molecules in control or schizophrenia groups.

3.5 Protein levels of mGluR5 and its trafficking molecules in the hippocampus of APD treated rats

To assess the effects of current antipsychotic medications on the mGluR5 system, two-way ANOVA
were used to compare the effects of haloperidol and olanzapine treatment (8, 16 or 36 days) on protein
levels of mGluR5 (total, monomer or dimer), Norbin and Tamalin proteins in the hippocampus. There
were no significant effects of olanzapine or haloperidol treatment overall or following the specific
treatment periods (F≥0.229, p≥0.296).
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4. Discussion

In the present study, we provide the first evidence that protein expression of mGluR5 is significantly
higher (total: 42%; monomer: 25%; dimer: 52%) in the hippocampal CA1 region of schizophrenia
subjects relative to healthy controls. Schizophrenia subjects also show a marked increase in Norbin,
and Tamalin proteins (47% and 34% respectively), which are endogenous regulators of mGluR5 signalling and trafficking not before analysed in neuropsychiatric pathology. In addition, we found no
influence of APD treatment on mGluR5 regulatory proteins in human subjects, however a negative
association between lifetime APD dose and mGluR5 protein expression levels was observed in schizophrenia subjects. There were no alterations in mGluR5 or its trafficking molecules in the hippocampus in response to APD treatment in our animal model.

mGluR5 activation in CA1 is critically involved in cognitive functions via mGluR5-mediated modulation of synaptic plasticity (Mukherjee and Manahan-Vaughan, 2013). mGluR5 knockout mice display
deficits in CA1-dependent LTP, coupled with deficits in spatial learning and memory (Lu et al.,
1997). mGluR5 PAMs, which upregulate mGluR5 activity, have been reported to enhance hippocampal-dependent LTP and LTD in the CA1 region, congruent with improved performance in the Morris
water maze, a measure of hippocampal-dependent spatial learning (Ayala et al., 2009). mGluR5dependent differences in spatial learning in rats correlated with measures of synaptic plasticity in CA1
and with mGluR5 protein levels (Manahan-Vaughan and Braunewell, 2005). As cognitive
dysfunction is a common symptom among schizophrenia patients (Harvey, 2013), the observed
increase in mGluR5 in the present study likely represents a compensatory upregulation for mGluR5
dysfunction in this region or in response to wider deficits in glutamatergic signalling. As recently
reviewed by Rubio Hu and colleagues (2014), reductions in the ionotropic glutamatergic receptors,
NMDA (Vrajová et al., 2010), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA;
Eastwood et al., 1997, 1995) and kainate (Benes et al., 2001), have been reported in the hippocampus.
Although one study also reported no changes in these receptors (Breese et al., 1995), it is notable that
there has been no increase detected.

In support of a deficit in mGluR5, Timms and colleagues recently reported the presence of a missense
mutation in the mGluR5 gene in a schizophrenia pedigree, transmitting to the extracellular domain of
the mGluR5 protein and likely altering mGluR5 sensitivity to glutamate (Timms et al., 2013). Additionally, the authors reported a frameshift mutation (P1148fs) that caused deletion of the Tamalinbinding site on the carboxyl tail of mGluR5, disrupting Tamalin/mGluR5 interactions and increasing
mGluR5 internalisation in primary hippocampal cultures (Timms et al., 2013). We have also recently
discovered the significant association of a single nucleotide polymorphism, located in the regulatory
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3’ untranslated region (highly involved in regulation of protein-protein interactions) within the GRM5
gene, and schizophrenia in a Caucasian case-control population (unpublished results). Considering
this evidence, Tamalin (but also Norbin) proteins might be upregulated in schizophrenia to compensate for reduced protein-protein interactions. Whilst Norbin has been previously demonstrated to positively regulate mGluR5 signalling (Wang et al., 2009), both Norbin and Tamalin are also critical regulators of mGluR5 trafficking (Kitano et al., 2002; Wang et al., 2009). Therefore our finding of increased levels of these proteins further support that mGluR5 signalling might be altered in the CA1
region of schizophrenia subjects, and these trafficking molecules are upregulated in an attempt to
compensate for alterations to mGluR5 signalling and trafficking.

Although it is accepted that mGluR5 is expressed on the postsynaptic neuronal membrane, increasing
evidence supports that the majority (60-90%) of mGluR5 is distributed at intracellular locations, including the endoplasmic reticulum membrane and nuclear membrane (Jong et al., 2014). Depending
on its cellular location, mGluR5 reportedly activates different signalling cascades leading to unique
cellular responses (Jong et al, 2009). In accordance, intracellular and extracellular mGluR5 differentially mediate synaptic plasticity in the CA1: cell surface receptors contribute to both LTD and LTP,
whereas activation of intracellular mGluR5 are involved in LTD only (Purgert et al., 2014). Considering our finding of alterations to proteins that regulate mGluR5 movement to/from neuronal membranes, using total homogenate preparations, it will be important to determine whether the increase in
mGluR5 observed in this study represents increases in intracellular or cell-surface distribution of
mGluR5, or both.

Premortem APD exposure can influence molecular measures in postmortem tissue analyses. In the
present study, estimated lifetime APD exposure was negatively correlated with mGluR5 monomer
levels and a correlation approaching significance was observed with mGluR5 dimers. This finding
suggests an influence of APD on mGluR5 protein levels in the CA1 whereby APDs might act to
reduce mGluR5 protein levels in the CA1. However considering we conversely detected increased
mGluR5 protein levels in this region, and we found no influence of APD treatment on mGluR5 in the
hippocampus of APD treated rats, it is unlikely that APD exposure is confounding the results of our
study. Furthermore, we additionally report no assocation between Norbin, Tamalin, and APDs in our
present human or rat studies, and we have previously reported that mGluR5 binding was not associated with APD exposure in the hippocampus (Matosin et al., 2013). Thus although an interaction is
unlikely, additional studies are required to explore the mechanism underlying a potential association.
Further investigation of the consequences of APD treatment on the mGluR5 system in animal models
of schizophrenia would be valuable.
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mGluR5 is a promising therapeutic target for the treatment of cognitive deficits in schizophrenia
(Matosin and Newell, 2013). The present study reports that mGluR5 and mGluR5 trafficking molecules are altered in the CA1 region in subjects with schizophrenia, suggesting that mGluR5 signalling
and trafficking is altered. It will be important for future studies to elucidate the exact mechanisms underlying these alterations and their implications for novel mGluR5-targeting therapeutics, to determine how to best target mGluR5 (if at all) in a manner that will be therapeutic in the context of pathological alterations. For example, altered cell surface expression might limit available targets for drugs
aimed at mGluR5 and the use of pharmacological chaperones to attenuate mGluR5 trafficking deficits
may be beneficial (Ulloa-Aguirre and Conn, 2011), whilst insensitivity to glutamate (as proposed by
Timms et al., 2013) may positively or negatively affect PAMs that rely on simultaneous glutamate
activation.

We conclude that hippocampal CA1 protein levels of mGluR5 and mGluR5 trafficking molecules are
increased in the pathology of schizophrenia. We hypothesise that this may be related to a functional
deficit within mGluR5, whereby glutamate sensitivity, protein-protein interactions or mGluR5 localisation are affected. Due to the prominent role of hippocampal mGluR5 in the emergence of learning
and memory deficits, we further suggest that alterations to mGluR5 in CA1 may be associated with an
imbalance of LTD:LTP, thus contributing to cognitive dysfunctions that are observed in schizophrenia patients. However, future studies investigating the correlation between hippocampal mGluR5 expression and cognition in humans is required to confirm this hypothesis.
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Figures and Tables

Figure 1. Protein levels of mGluR5 in the CA1 region of subjects with schizophrenia and
matched controls. (a) Representative immunoblots, and normalised levels of mGluR5 (b) total, (c)
monomer, and (d) dimer protein measures, in schizophrenia subjects compared to controls. Abbreviations: Ct: control; kDa: kilodaltons; Ln: natural logarithm; mGluR5: metabotropic glutamate receptor
5; Sz: schizophrenia. *P<0.05, **P<0.01, ***P<0.001.
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Figure 2. mGluR5 trafficking molecules Norbin and Tamalin in the CA1 region of subjects with
schizophrenia. (a) Representative immunoblots, and normalised protein levels of mGluR5 trafficking
molecules (b) Norbin and (c) Tamalin in the CA1 region of subjects with schizophrenia compared to
matched controls. Abbreviations: Ct: control; kDa: kilodaltons; Ln: natural logarithm; Sz: schizophrenia. *P<0.05, **P<0.01, ***P<0.001.
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Table 1. Demographic and clinical characteristics of the postmortem cohort.
CA1 (n=20/group)
Control

Schizophrenia

Brain pH

6.6 ± 0.03

6.6 ± 0.3

Postmortem interval (hours)

26.1 ± 12.8

28.8 ± 14.1

RNA integrity number

7.2 ± 0.7

7.2 ± 0.5

Age at Death (years)

58.2 ± 12.6

55.5 ± 13.5

Gender

2 F, 18 M

9 F, 11 M

Hemisphere

13 R, 7L

10R, 10L

Age of disease onset (years)

-

23.5 ± 6.8

Duration of illness (years)
Lifetime antipsychotic drug medication*

-

32.05 ± 13.7
668 ± 421

Antidepressant history (yes/no)

-

12

*Standardised chlorpromazine equivalent, mg.
Abbreviations: DLPFC: dorsolateral prefrontal cortex; F: female; L: left; M:
male; R: right. Data are expressed as mean ± standard deviation
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Table 2. Spearman's Correlations for continuous clinical and demographic variables and protein
levels of mGluR5 total, monomer and dimer, and mGluR5 trafficking molecules Norbin and Tamalin, in the hippocampal CA1 region. Significant values (p<0.05) are highlighted in bold.
Variable

Brain pH

Age at Death

Postmortem
interval

Freezer storage time

Brain weight

Age of disease
onset

Duration of
illness

Lifetime
antipsychotic
drug intake*

All subjects
mGlu mGlu
mGlu R5
R5
R5
(mon- (diTa(total) omer) mer) Norbin malin
r=- r=r =r=
r=
0.355 0.001 0.088 0.015 0.026
p=
p=
p
p=
p=
0.026 0.993 =0.593 0.929 0.874
r=r=r =r=r=0.028 0.154 0.164 0.096 0.096
p=
p=
p=
p=
p=
0.868 0.349 0.320 0.561 0.560
r=r=
r=
r=r=0.167 0.100 0.170 0.051 0.085
p=
p=
p=
p=
p=
0.309 0.546 0.302 0.758 0.606
r=
r
r=
r=
r=
0.356 =0.243 0.347 0.173 0.159
p=
p
p
p=
p=
0.026 =0.136 =0.030 0.292 0.334
r=r=r=r=r=0.144 0.039 0.232 0.258 0.176
p=
p=
p=
p=
p=
0.383 0.815 0.156 0.113 0.283

mGlu
R5
(total)
r=0.304
p=
0.192
r=0.188
p=
0.427
r=0.199
p=
0.400
r=
0.274
p=
0.243
r=0.267
p=
0.255

mGlu
R5
(monomer)
r=0.040
p=
0.867
r=0.087
p=
0.716
r=0.199
p=
0.401
r=
0.335
p=
0.149
r=0.083
p=
0.729

Controls
mGlu
R5
(diTamer) Norbin malin
r=r=
r=
0.134 0.142 0.127
p=
p=
p=
0.573 0.551 0.593
r=
r=r=0.136 0.068 0.061
p=
p=
p=
0.569 0.777 0.798
r=r=
r=
0.118 0.113 0.049
p=
p=
p=
0.620 0.635 0.838
r=
r=
r=
0.332 0.219 0.162
p=
p=
p=
0.152 0.354 0.496
r=r=r=0.170 0.123 0.042
p
p=
p=
=0.473 0.606 0.860

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Schizophrenia
mGlu mGlu
mGlu R5
R5
R5
(mon- (diTa(total) omer) mer) Norbin malin
r=r=r =r=r=0.448 0.084 0.116 0.170 0.147
p=
p=
p=
p=
p=
0.055 0.732 0.497 0.486 0.549
r=
r=r=r=r=0.287 0.184 0.211 0.199 0.187
p=
p
p=
p=
p=
0.233 =0.452 0.386 0.414 0.444
r=r=
r=
r=r=0.328 0.250 0.359 0.158 0.170
p=
p=
p=
p=
p=
0.170 0.302 0.131 0.517 0.487
r=
r=
r=
r=
r=
0.531 0.207 0.354 0.220 0.210
p=
p
p=
p=
p=
0.019 =0.395 0.137 0.365 0.389
r=
r=r=r=r=0.030 0.069 0.194 0.145 0.142
p=
p=
p=
p=
p=
0.903 0.780 0.425 0.553 0.563
r=
r=
r=
r=
r=
0.259 0.241 0.156 0.051 0.078
p=
p=
p=
p=
p=
0.285 0.321 0.523 0.837 0.750
r=
r=r=r=r=0.199 0.234 0.232 0.231 0.224
p=
p=
p=
p=
p=
0.415 0.336 0.339 0.341 0.357
r=r=- r=r=r=0.160 0.502 0.426 0.251 0.256
p=
p=
p=
p=
p=
0.514 0.029 0.069 0.300 0.290

* Standardised chlorpromazine equivalent (mg)
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Table 3. Spearman’s correlations for associations between protein levels of mGluR5 (total, monomer and dimer) and novel mGluR5 signalling partners Norbin and Tamalin, within (A) control
and (B) schizophrenia subjects. Significant values (p<0.05) are highlighted in bold.
A. Control
mGluR5 (total)

mGluR5 total
r = 0.066
p = 0.782
r = 0.102
p = 0.668
r = -0.036
p = 0.980
r = 0.017
p = 0.945

mGluR5 monomer
r = 0.066
p = 0.782
r = 0.853
p < 0.001
r = 0.274
p = 0.243
r = 0.334
p = 0.150

mGluR5 dimer
r = 0.102
p = 0.668
r = 0.853
p < 0.001
r = 0.266
p = 0.257
r = 0.292
p = 0.212

B. Schizophrenia

mGluR5 total

mGluR5 monomer

mGluR5 dimer

mGluR5(total)

r = 0.140
p = 0.557
r = 0.137
p = 0.566
r = 0.037
p = 0.876
r = 0.027
p = 0.910

r = 0.140
p = 0.557
r = 0.790
p < 0.001
r = 0.001
p = 0.996
r = 0.038
p = 0.875

r = 0.137
p = 0.566
r = 0.790
p < 0.001
r = 0.064
p = 0.788
r = 0.029
p = 0.902

mGluR5 (monomer)
mGluR5 (dimer)
Norbin
Tamalin

mGluR5(monomer)
mGluR5 (dimer)
Norbin
Tamalin

$
$

$

$
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